var title_f39_5_40016="Wall push-up exercise";
var content_f39_5_40016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strength exercise: Wall push-up",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These push-ups will strengthen your arms, shoulders, and chest. Try this exercise during a TV commercial break.",
"    <ol>",
"     <li>",
"      Face a wall, standing a little farther than arm's length away, feet shoulder-width apart.",
"     </li>",
"     <li>",
"      Lean your body forward and put your palms flat against the wall at shoulder height and shoulder-width apart.",
"     </li>",
"     <li>",
"      Slowly breathe in as you bend your elbows and lower your upper body toward the wall in a slow, controlled motion. Keep your feet flat on the floor.",
"     </li>",
"     <li>",
"      Hold the position for one second.",
"     </li>",
"     <li>",
"      Breathe out and slowly push yourself back until your arms are straight.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 times.",
"     </li>",
"     <li>",
"      Rest; then repeat 10 to 15 more times.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40016=[""].join("\n");
var outline_f39_5_40016=null;
var title_f39_5_40017="capillary nail loop a";
var content_f39_5_40017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Capillary loop dilatation in a patient with dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H. Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40017=[""].join("\n");
var outline_f39_5_40017=null;
var title_f39_5_40018="Patient information: Heel pain (caused by plantar fasciitis) (The Basics)";
var content_f39_5_40018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15441\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/7/25713\">",
"         Plantar fasciitis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/26/35240\">",
"          Exercises that can help with heel pain",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/9/15507\">",
"           Foot taping for plantar fasciitis",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/42/38561\">",
"         Patient information: Heel pain (caused by plantar fasciitis) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Heel pain (caused by plantar fasciitis) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/heel-pain-caused-by-plantar-fasciitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H472262592\">",
"      <span class=\"h1\">",
"       What causes heel pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;One of the most common causes of heel pain is a problem called &ldquo;plantar fasciitis.&rdquo; Plantar fasciitis is the term doctors use when a part of the foot called the plantar fascia gets irritated or swollen. The plantar fascia is a tough band of tissue that connects the heel bone to the toes (",
"      <a class=\"graphic graphic_figure graphicRef73704 \" href=\"mobipreview.htm?25/7/25713\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Heel pain caused by plantar fasciitis is very common. It often affects people who run, jump, or stand for long periods. Most people who get this type of heel pain get better within a year even if they do not get treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472262599\">",
"      <span class=\"h1\">",
"       What are the symptoms of plantar fasciitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptom is pain under the heel and sole (bottom) of the foot. The pain is often worst when you first get out of bed in the morning. It can also be bad when you get up after being seated for some time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472262606\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Rest",
"        </strong>",
"        &mdash; Give your foot a chance to heal by resting. But don't completely stop being active. Doing that can lead to more pain and stiffness in the long run.",
"       </li>",
"       <li>",
"        <strong>",
"         Ice your foot",
"        </strong>",
"        &mdash; Putting ice on your heel for 20 minutes up to 4 times a day might relieve pain. Icing and massaging your foot before exercise might also help.",
"       </li>",
"       <li>",
"        <strong>",
"         Do special foot exercises",
"        </strong>",
"        &mdash; Certain exercises can help with heel pain. Do these exercises every day (",
"        <a class=\"graphic graphic_figure graphicRef73613 \" href=\"mobipreview.htm?34/26/35240\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        <strong>",
"         Take pain medicines",
"        </strong>",
"        &mdash; If your pain is severe, you can try taking pain medicines that you can get without a prescription. Examples include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sold as Advil&reg; or Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sold as Aleve&reg;). But if you have other medical conditions or already take other medicines, ask your doctor or nurse before taking new pain medicines.",
"       </li>",
"       <li>",
"        <strong>",
"         Wear sturdy shoes",
"        </strong>",
"        &mdash; Sneakers with a lot of cushion and good arch and heel support are best. Shoes with rigid soles can also help. Adding padded or gel heel inserts to your shoes might help, too.",
"       </li>",
"       <li>",
"        <strong>",
"         Wear splints at night",
"        </strong>",
"        &mdash; Some people feel better if they wear a splint while they sleep that keeps their foot straight. These splints are sold in drugstores and medical supply stores.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472262613\">",
"      <span class=\"h1\">",
"       Is there a test for plantar fasciitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. He or she may suggest an X-ray, or other tests to check whether your symptoms might be caused by something else.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472262620\">",
"      <span class=\"h1\">",
"       How is plantar fasciitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The first step is to try the things you can do on your own. But if you do not get better, or your symptoms are severe, your doctor or nurse might suggest:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Taping up your foot in a special way that helps the support the foot (",
"        <a class=\"graphic graphic_picture graphicRef53721 \" href=\"mobipreview.htm?15/9/15507\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Special shoe inserts, made to fit your foot",
"       </li>",
"       <li>",
"        Shots (that go into your foot) of a medicine called a steroid, which can help bring down swelling",
"       </li>",
"       <li>",
"        Putting a cast over your foot and ankle",
"       </li>",
"       <li>",
"        Surgery (this is an option only in some cases that do not get better with other treatments)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some doctors also suggest a treatment called &ldquo;shock wave therapy.&rdquo; This treatment is painful and has not been proven to work.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472262627\">",
"      <span class=\"h1\">",
"       Is there anything I can do to keep from getting heel pain again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To reduce the chances that your pain will come back:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wear shoes that fit well, have a lot of cushion, and support the heel and ankle",
"       </li>",
"       <li>",
"        Avoid wearing slippers, flip-flops, slip-ons, or poorly fitted shoes",
"       </li>",
"       <li>",
"        Avoid going barefoot",
"       </li>",
"       <li>",
"        Do not wear worn-out shoes",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472262634\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/42/38561?source=see_link\">",
"       Patient information: Heel pain (caused by plantar fasciitis) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/5/40018?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15441 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40018=[""].join("\n");
var outline_f39_5_40018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472262592\">",
"      What causes heel pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472262599\">",
"      What are the symptoms of plantar fasciitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472262606\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472262613\">",
"      Is there a test for plantar fasciitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472262620\">",
"      How is plantar fasciitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472262627\">",
"      Is there anything I can do to keep from getting heel pain again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472262634\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15441\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/7/25713\">",
"      Plantar fasciitis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/26/35240\">",
"       Exercises that can help with heel pain",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/9/15507\">",
"        Foot taping for plantar fasciitis",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/42/38561?source=related_link\">",
"      Patient information: Heel pain (caused by plantar fasciitis) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_5_40019="Heaney clamp";
var content_f39_5_40019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heaney clamp with longitudinal serration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40019=[""].join("\n");
var outline_f39_5_40019=null;
var title_f39_5_40020="Chlorpropamide: Patient drug information";
var content_f39_5_40020=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlorpropamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     see \"Chlorpropamide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Chlorpropamide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlorpropamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem or type 1 diabetes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with other high blood sugar (diabetes) drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695917",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with the first meal of the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12071 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40020=[""].join("\n");
var outline_f39_5_40020=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013812\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013811\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013816\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013817\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013819\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013814\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013815\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013820\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013821\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=related_link\">",
"      Chlorpropamide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_5_40021="Lichenoid drug eruption";
var content_f39_5_40021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous to violaceous papules with fine scale are present in this patient with a lichenoid drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40021=[""].join("\n");
var outline_f39_5_40021=null;
var title_f39_5_40022="Strychnine poisoning";
var content_f39_5_40022=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Strychnine poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/5/40022/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40022/contributors\">",
"     Kavita M Babu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/5/40022/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40022/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/5/40022/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40022/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/5/40022/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strychnine, an alkaloid derived from seeds of the tree Strychnos nux vomica, was first used as a rodenticide in Germany in the early 16",
"    <sup>",
"     th",
"    </sup>",
"    century. By the early 1900s, strychnine became widely available in cathartic pills, and caused a significant number of fatalities from suicidal and unintentional ingestions in the United States (US). In the early 1900s, strychnine toxicity was a major cause of toxicologic death in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The number of strychnine exposures in the United States has fallen significantly since its elimination from nonprescription preparations in 1962 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although rare, most strychnine poisonings today result from the adulteration of street drugs (eg, cocaine, heroin), as well as from small amounts found in herbal medications and homeopathic remedies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/3\">",
"     3",
"    </a>",
"    ]. Rarely, cases of poisoning occur in which a strychnine-containing rodenticide is implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the basic pharmacology, clinical presentation, and management of strychnine poisoning. Discussions of the general approach to the management of poisoned patients and detailed management of other toxins are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The seeds of Strychnos nux vomica contain 1.1 to 1.4 percent of strychnine and brucine, another toxic alkaloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/7\">",
"     7",
"    </a>",
"    ]. Commercial rodenticide preparations typically contain between 0.3 to 5.0 percent strychnine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Strychnine is typically formulated as a relatively odorless and tasteless white powder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strychnine is a competitive antagonist of glycine, an important inhibitory neurotransmitter in the spinal cord, brainstem, and higher centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/9\">",
"     9",
"    </a>",
"    ]. Strychnine's toxicity is attributed to action at the postsynaptic receptor in the motor neurons of the spinal cord's neural horn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/7\">",
"     7",
"    </a>",
"    ]. There, it antagonizes inhibitory tone, resulting in powerful and uncontrollable muscle contractions. Additional mechanisms have been proposed, including agonism of excitatory NMDA receptors and antagonism of gamma amino butyric acid (GABA), another inhibitory neurotransmitter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strychnine is rapidly absorbed from all routes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. The onset of symptoms occurs within 10 to 20 minutes of ingestion, while injection or inhalation may result in more rapid development of symptoms, and dermal exposure may produce a delayed onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Strychnine displays little protein binding and is rapidly redistributed from the blood to the tissues. Its volume of distribution is 13",
"    <span class=\"nowrap\">",
"     L/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/1,2,15\">",
"     1,2,15",
"    </a>",
"    ]. Elimination follows first-order kinetics with an elimination half-life of approximately 10 to 16 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/13,16,17\">",
"     13,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic metabolism eliminates approximately 80 percent of ingested strychnine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Inducers of hepatic microsomal enzyme activity can enhance strychnine metabolism, while deacetylation can reduce the drug's biologic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/6\">",
"     6",
"    </a>",
"    ]. Up to 20 percent of ingested strychnine may be eliminated in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2,13,20,21\">",
"     2,13,20,21",
"    </a>",
"    ]. However, in massive ingestions urinary excretion appears to play a lesser role, accounting for the excretion of as little as 1 percent of the amount ingested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/21\">",
"     21",
"    </a>",
"    ]. Strychnine is also concentrated and excreted in the bile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's history should include a detailed description of events leading up to presentation. The clinician should ask about depression, intentional self-injury, exposure to dietary supplements, occupational exposure to pesticide, and use of illicit drugs. Additional history regarding trauma, past medical history, and current medications will help to narrow the differential diagnosis and identify coingestants.",
"   </p>",
"   <p>",
"    The onset of symptoms from strychnine poisoning usually occurs within 10 to 20 minutes of ingestion, but injection or inhalation may result in more rapid development, and dermal exposure may produce a delayed onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prodromal signs may include mydriasis, hypervigilance, anxiety, hyperreflexia, clonus, and stiffness of the facial and neck muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/22\">",
"     22",
"    </a>",
"    ]. Spontaneous vomiting following oral exposure is unusual in strychnine poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sine qua non of strychnine toxicity is the \"awake\" or \"spinal\" seizure, in which the patient demonstrates tonic-clonic seizure activity but remains fully alert throughout and afterwards. Characteristic muscle spasms may include opisthotonos (truncal rigidity and back arching), as well as marked grimacing (risus sardonicus, or sardonic smile) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/13\">",
"     13",
"    </a>",
"    ]. Muscle contractions typically follow a waxing and waning course, with minutes of tetanic contraction followed by up to two minutes of muscle relaxation, or even flaccidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/3,20\">",
"     3,20",
"    </a>",
"    ]. Stimulation may provoke or worsen the spasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tetanic contraction of skeletal muscle produces rigidity, tachycardia, and hyperthermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/7\">",
"     7",
"    </a>",
"    ]. Rhabdomyolysis and compartment syndrome can result. Patients may also develop a severe lactic acidosis from uncontrolled muscle activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/24\">",
"     24",
"    </a>",
"    ]. Involvement of thoracic and diaphragmatic musculature leads to respiratory paralysis, the most common cause of death in strychnine toxicity. Prognosis is generally favorable if the patient survives beyond five hours from the onset of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2\">",
"     2",
"    </a>",
"    ]. Neuromuscular sequelae are rare among survivors; however, prolonged weakness, myalgia, myoedema, and anterior tibial compartment syndrome have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2,6,12\">",
"     2,6,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of strychnine toxicity includes tetanus, epilepsy, dystonic drug reactions, infections of the neck, hypocalcemia, picrotoxin exposure, and psychogenic disorders.",
"   </p>",
"   <p>",
"    Tetanus classically presents with trismus, followed by diffuse spasms of the neck and extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/12\">",
"     12",
"    </a>",
"    ]. Tetanospasmin blocks the release of glycine from inhibitory neurons, producing hyperexcitability more slowly than strychnine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/6\">",
"     6",
"    </a>",
"    ]. Symptoms of tetanus generally progress over days. A history of recent penetrating injury and inadequate immunization status may support this diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link\">",
"     \"Tetanus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    True generalized tonic-clonic seizures can be distinguished from strychnine toxicity by the presence of an altered level of consciousness and a postictal period. The finding of an altered sensorium in a patient with involuntary muscle activity should prompt a search for etiologies other than strychnine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dystonic drug reactions and infections of the neck may mimic facial grimacing seen with strychnine, with less of the diffuse tonic-clonic activity. A history of exposure to an antipsychotic or antiemetic medication and improvement with anticholinergic therapy support the diagnosis of dystonia.",
"   </p>",
"   <p>",
"    Hypocalcemia may present with hyperexcitability, tetany, focal numbness, and diffuse muscle spasms. Typically the findings are not as severe as in strychnine toxicity, and a serum calcium level quickly reveals the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clenbuterol, a beta-agonist commonly used to adulterate heroin, typically causes tachycardia, tremor, anxiety, and vomiting. However, cases of clenbuterol toxicity presenting with agitation, muscle spasm, hyperreflexia, and elevated serum creatine kinase concentrations have been reported. The authors specifically note the similarity in presentation to strychnine toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Picrotoxin inhibits the action of gamma-aminobutyric acid (GABA) leading to convulsions that develop more slowly than with strychnine poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/6\">",
"     6",
"    </a>",
"    ]. This outdated analeptic is not widely available.",
"   </p>",
"   <p>",
"    Psychogenic causes for involuntary muscle contractions should be considered a diagnosis of exclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although identification and measurement of strychnine in blood and urine has been described, rapid laboratory tests specific for detecting and quantifying strychnine are unavailable in most clinical settings. Close correlation between strychnine levels and clinical toxicity has not been demonstrated. Clinical features guide management; the main value of laboratory analysis lies in confirmation of the exposure and identification of complications, such as rhabdomyolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine laboratory evaluation of any acutely poisoned patient should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions.",
"     </li>",
"     <li>",
"      Electrocardiogram, to rule out conduction system poisoning by coingestants that affect the QRS or QTc intervals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other potentially useful laboratory studies in the setting of strychnine poisoning include: complete blood count; basic electrolytes, including potassium and calcium; creatinine and BUN; creatine phosphokinase; and urinalysis. With strychnine toxicity, a leukocytosis may develop, and a lactic acidosis can occur due to the intensity of muscle activity. Hypokalemia has been reported in the setting of strychnine exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/27\">",
"     27",
"    </a>",
"    ]. Creatine phosphokinase and myoglobinuria are useful markers of rhabdomyolysis, and early assessment of renal function is indicated as renal failure may result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any poisoning, management begins with rapid assessment of the patient's airway, breathing, and circulation. Oxygen is administered, intravenous access established, and continuous cardiac monitoring employed. Fingerstick serum glucose is immediately obtained. Prompt recognition of the poisoning and initiation of treatment is critical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/24\">",
"     24",
"    </a>",
"    ]. The patient should be managed in a quiet, dark room to avoid all extraneous stimuli; excessive manipulation and loud noises may precipitate paroxysms of muscle activity secondary to reflex hyperexcitability.",
"   </p>",
"   <p>",
"    Given their rarity and complexity, all cases of suspected strychnine toxicity should be managed in conjunction with a poison control center or medical toxicologist. (See",
"    <a class=\"local\" href=\"#H7788230\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Control of muscle activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive control of muscle activity is the cornerstone to successful management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2\">",
"     2",
"    </a>",
"    ]. High dose benzodiazepines are the mainstay for controlling muscle activity. In adults, treatment with 5 to 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    may be initiated, with rapid titration to effect; amounts as large as 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of diazepam have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In the presence of benzodiazepines, gamma amino butyric acid (GABA) has increased affinity for its receptor, causing increased inhibitory tone at the level of the motor neuron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/1\">",
"     1",
"    </a>",
"    ]. Because strychnine affects glycine receptors, not GABA receptors, benzodiazepines may not provide adequate pharmacologic reversal in severe strychnine toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barbiturates may also be efficacious, and provide synergy with benzodiazepines in refractory cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2\">",
"     2",
"    </a>",
"    ]. If more than 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , or 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , are given without significant improvement in the patient's condition, we suggest the addition of a barbiturate to further control muscle activity.",
"   </p>",
"   <p>",
"    The use of barbiturates may necessitate elective intubation to avoid CNS and respiratory depression. In the intubated patient,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    can be initiated with a 125 to 300",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    continuous infusion and titrated to effect. Propofol should not be used routinely in children under the age of two.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    may also be used; its safety in children has been well-documented. A loading dose of 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    can be given, followed by additional doses of 5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 20 minutes.",
"   </p>",
"   <p>",
"    Involuntary muscle contractions can be extremely painful, and appropriate analgesia should be given. However, opioids should be titrated carefully to avoid hypoventilation; a short-acting agent, like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , may be most appropriate in critical patients. Fentanyl can be administered in intermittent doses at 0.5 to 1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    IV; further doses may be repeated every 5 to 15 minutes as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Airway management and paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most deaths result from respiratory compromise, and emergent airway management is often necessary with a significant acute ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2\">",
"     2",
"    </a>",
"    ]. Sedation, paralysis, and endotracheal intubation are necessary in the setting of uncontrollable motor activity, severe acidosis (pH &lt;7.1), or significant hyperthermia (core temperature above 40&ordm;C).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV is an appropriate induction agent for use in rapid sequence intubation (RSI).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    are good alternative induction agents. We prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV or another nondepolarizing neuromuscular blocking agent if RSI is performed in the strychnine-poisoned patient, given the potential for transiently increased muscle activity with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=see_link\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benzodiazepines or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    may be used for sedation following intubation. It is imperative that the patient be well sedated while paralyzed. Long-acting nondepolarizing agents may be used after intubation (eg, doxacurium 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    with a duration of 100 minutes;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    0.010 to 0.015",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    with a duration of 15 minutes), particularly in the setting of hyperthermia. While additional evaporative cooling methods may be used, paralysis is the most rapid and effective means for reversing hyperthermia and acidosis in these patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    has no role in the long-term paralysis of these patients, given its potential to cause hyperkalemia and hyperthermia, and to worsen rhabdomyolysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15913?source=see_link\">",
"     \"Accidental hypothermia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Additional management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care and monitoring for complications is crucial. Intravenous fluids should be given in sufficient amounts to maintain brisk urine output (above 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour), as rhabdomyolysis, metabolic acidosis, and acute renal failure are well-known complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. Serial examinations and appropriate surgical consultation for compartment syndrome are necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no role for ipecac or gastric lavage in strychnine toxicity. Multidose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    may be beneficial as the high strychnine concentration found in the hepatobiliary system suggests enterohepatic recirculation, but benefit is unproven. The use of charcoal should be avoided in any patient with a tenuous airway or altered mental status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. There is no demonstrated role for hemodialysis in enhancing elimination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strychnine poisoning in the pediatric population parallels that in adults; pathophysiology and clinical manifestations are the same. However, diagnosing strychnine poisoning in children can be difficult. Young children may be unable to communicate vague symptoms; adolescents may be reluctant to disclose their use of recreational drugs, which may be adulterated with strychnine.",
"   </p>",
"   <p>",
"    As with adults, the key to management is controlling involuntary muscle activity, administering supportive care, and treating complications. Supportive care is of the utmost importance and includes: administration of oxygen and intravenous fluids, continuous cardiac monitoring, and correction of vital signs.",
"   </p>",
"   <p>",
"    The starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    in children is 0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    with rapid titration to effect. Vigilance for signs of respiratory muscle fatigue is essential. End-tidal CO2 monitoring may be a useful adjunct for early identification of hypoventilation. Children must be managed in a center with expertise in pediatric emergency airway management. Complications of rhabdomyolysis, metabolic acidosis, renal failure, and compartment syndrome should be treated aggressively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pediatric exposures to strychnine occur worldwide, often in the developing world where use of strychnine as a pesticide continues. Some rodenticide formulations of strychnine are sold as bright pink tablets, making them appealing to small children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40022/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7788230\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strychnine poisoning is rare and generally results from the adulteration of street drugs (eg, cocaine, heroin), small amounts found in herbal medications and homeopathic remedies, and strychnine-containing rodenticides.",
"     </li>",
"     <li>",
"      Strychnine's toxicity antagonizes inhibitory tone in motor neurons of the spinal cord's neural horn, resulting in powerful and uncontrollable muscle contractions. Strychnine's pharmacology and kinetics are discussed above. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and cellular toxicology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Kinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of symptoms from strychnine poisoning usually occurs within 10 to 20 minutes of ingestion, but injection or inhalation may result in more rapid development, and dermal exposure may produce a delayed onset. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sine qua non of strychnine toxicity is the \"awake\" seizure, in which the patient demonstrates tonic-clonic activity but remains fully alert throughout and afterwards. Characteristic muscle spasms may include truncal rigidity and back arching, as well as marked grimacing. Muscle contractions typically follow a waxing and waning course, with minutes of tetanic contraction followed by up to two minutes of muscle relaxation, or even flaccidity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of strychnine toxicity includes tetanus, epilepsy, dystonic drug reactions, infections of the neck, hypocalcemia, picrotoxin exposure, and psychogenic disorders. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid laboratory tests specific for detecting and quantifying strychnine are unavailable in most clinical settings. The main value of laboratory analysis lies in confirmation of the exposure and identification of complications, such as rhabdomyolysis. Laboratories indicated in the management of strychnine poisoning are described above. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aggressive control of muscle activity is the cornerstone to successful management. We suggest treatment with high dose benzodiazepines to control muscle activity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Barbiturates may also be efficacious, and provide synergy with benzodiazepines in refractory cases. Management is discussed in detail above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most deaths result from respiratory compromise, and emergent airway management is often necessary with a significant acute ingestion. Sedation, paralysis, and endotracheal intubation are necessary in the setting of uncontrollable motor activity, severe acidosis (pH &lt;7.1), or significant hyperthermia (core temperature above 40&ordm;C). For rapid sequence intubation, we use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      for paralysis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/1\">",
"      Heiser JM, Daya MR, Magnussen AR, et al. Massive strychnine intoxication: serial blood levels in a fatal case. J Toxicol Clin Toxicol 1992; 30:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/2\">",
"      Smith BA. Strychnine poisoning. J Emerg Med 1990; 8:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/3\">",
"      Chan TY. Herbal medicine causing likely strychnine poisoning. Hum Exp Toxicol 2002; 21:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/4\">",
"      Katz J, Prescott K, Woolf AD. Strychnine poisoning from a Cambodian traditional remedy. Am J Emerg Med 1996; 14:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/5\">",
"      O'Callaghan WG, Joyce N, Counihan HE, et al. Unusual strychnine poisoning and its treatment: report of eight cases. Br Med J (Clin Res Ed) 1982; 285:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/6\">",
"      Boyd RE, Brennan PT, Deng JF, et al. Strychnine poisoning. Recovery from profound lactic acidosis, hyperthermia, and rhabdomyolysis. Am J Med 1983; 74:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/7\">",
"      Duverneuil C, de la Grandmaison GL, de Mazancourt P, Alvarez JC. Liquid chromatography/photodiode array detection for determination of strychnine in blood: a fatal case report. Forensic Sci Int 2004; 141:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/8\">",
"      Drost, ML. Strychnine overdose in man. Can Soc Forens Sci J 1979; 12:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/9\">",
"      Probst A, Cort&eacute;s R, Palacios JM. The distribution of glycine receptors in the human brain. A light microscopic autoradiographic study using [3H]strychnine. Neuroscience 1986; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/10\">",
"      Larson AA, Beitz AJ. Glycine potentiates strychnine-induced convulsions: role of NMDA receptors. J Neurosci 1988; 8:3822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/11\">",
"      Starretz-Hacham O, Sofer S, Lifshitz M. Strychnine intoxication in a child. Isr Med Assoc J 2003; 5:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/12\">",
"      Flood RG. Strychnine poisoning. Pediatr Emerg Care 1999; 15:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/13\">",
"      Palatnick W, Meatherall R, Sitar D, Tenenbein M. Toxicokinetics of acute strychnine poisoning. J Toxicol Clin Toxicol 1997; 35:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/14\">",
"      Greene R, Meatherall R. Dermal exposure to strychnine. J Anal Toxicol 2001; 25:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/15\">",
"      Sgaragli GP, Mannaioni PF. Pharmacokinetic observations on a case of massive strychnine poisoning. Clin Toxicol 1973; 6:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/16\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12-2001. A 16-year-old boy with an altered mental status and muscle rigidity. N Engl J Med 2001; 344:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/17\">",
"      Edmunds M, Sheehan TM, Van't Hoff W. Strychnine poisoning: clinical and toxicological observations on a non-fatal case. J Toxicol Clin Toxicol 1986; 24:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/18\">",
"      ADAMSON RH, FOUTS JR. Enzymatic metabolism of strychnine. J Pharmacol Exp Ther 1959; 127:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/19\">",
"      Mishima M, Tanimoto Y, Oguri Z, Yoshimura H. Metabolism of strychnine in vitro. Drug Metab Dispos 1985; 13:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/20\">",
"      Perper JA. Fatal strychnine poisoning--a case report and review of the literature. J Forensic Sci 1985; 30:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/21\">",
"      Dittrich K, Bayer MJ, Wanke LA. A case of fatal strychnine poisoning. J Emerg Med 1984; 1:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/22\">",
"      Santhosh GJ, Joseph W, Thomas M. Strychnine poisoning. J Assoc Physicians India 2003; 51:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/23\">",
"      Dickson E, Hawkins RC, Reynolds R. Strychnine poisoning: an uncommon cause of convulsions. Aust N Z J Med 1992; 22:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/24\">",
"      Wood D, Webster E, Martinez D, et al. Case report: Survival after deliberate strychnine self-poisoning, with toxicokinetic data. Crit Care 2002; 6:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/25\">",
"      Kirrane, BM, Kilbury, LL, Stajic, M, et, al. Clenbuterol toxicity masquerading as strychnine poisoning. Clin Toxicol 2006; 44:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/26\">",
"      Manini A, Labinson RM, Kirrane B, et al. A novel neuromuscular syndrome associated with clenbuterol-tainted heroin. Clin Toxicol (Phila) 2008; 46:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/27\">",
"      Ferguson MB, Vance MA. Payment deferred: strychnine poisoning in Nicaragua 65 years ago. J Toxicol Clin Toxicol 2000; 38:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/28\">",
"      Hardin JA, Griggs RC. Diazepam treatment in a case of strychnine poisoning. Lancet 1971; 2:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/29\">",
"      Maron BJ, Krupp JR, Tune B. Strychnine poisoning successfully treated with diazepam. J Pediatr 1971; 78:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40022/abstract/30\">",
"      Oberpaur B, Donoso A, Claver&iacute;a C, et al. Strychnine poisoning: an uncommon intoxication in children. Pediatr Emerg Care 1999; 15:264.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 310 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-89.218.100.194-DA315AB02B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40022=[""].join("\n");
var outline_f39_5_40022=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Control of muscle activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Airway management and paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Additional management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7788230\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15913?source=related_link\">",
"      Accidental hypothermia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_5_40023="Benazepril: Pediatric drug information";
var content_f39_5_40023=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benazepril: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"    see \"Benazepril: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/42/2726?source=see_link\">",
"    see \"Benazepril: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotensin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F139578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lotensin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1000076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin-Converting Enzyme (ACE) Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1000107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"      see \"Benazepril: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Dosage must be titrated according to patient&rsquo;s response; use lowest effective dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents: Oral: Initial: 0.2 mg/kg/dose once daily as monotherapy; maximum initial dose: 10 mg/",
"     <b>",
"      day",
"     </b>",
"     ; maintenance: 0.1-0.6 mg/kg/dose once daily; maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Oral:  Initial: 10 mg once daily in patients not receiving a diuretic; maintenance: 20-80 mg/day as a single dose or 2 divided doses; the need for twice daily dosing should be assessed by monitoring peak (2-6 hours after dosing) and trough blood pressure responses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     To decrease the risk of hypotension, patients taking diuretics should have diuretics discontinued 2-3 days prior to starting benazepril; diuretic may be resumed if blood pressure is not controlled with benazepril monotherapy. If diuretics cannot be discontinued prior to starting benazepril, then an initial dose of benazepril of 5 mg once daily should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Use is not recommended (insufficient data exists; dose not established)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Initial: 5 mg once daily, then increase as required to a maximum of 40 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotensin&reg;: 10 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5089236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F5687404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at temperatures &le;30&deg;C (86&deg;F); protect from moisture; dispense in tight container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1000077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, either alone or in combination with a thiazide diuretic (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F139619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benazepril may be confused with Benadryl&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lotensin&reg; may be confused with Lioresal&reg;, lorcaserin, lovastatin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F139617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Postural dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Serum creatinine increased, worsening of renal function may occur in patients with bilateral renal artery stenosis or hypovolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, alopecia, anaphylactoid reaction, angina, angioedema (includes head, neck and intestinal angioedema), arthralgia, arthritis, asthma, BUN increased (transient), dermatitis, dyspnea, ECG changes, eosinophilia, flushing, gastritis, hemolytic anemia, hyperbilirubinemia, hyperglycemia, hyperkalemia, hypersensitivity, hypertonia, hyponatremia, hypotension, impotence, insomnia, leukopenia, myalgia, neutropenia, orthostatic hypotension, palpitations, pancreatitis, paresthesia, pemphigus, peripheral edema, photosensitivity, proteinuria, pruritus, rash, shock, Stevens-Johnson syndrome, syncope, thrombocytopenia, transaminases increased, uric acid increased, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anaphylaxis, eosinophilic pneumonitis, neutropenia, agranulocytosis, renal failure, and renal insufficiency have been reported with other ACE inhibitors. In addition, a syndrome including arthralgia, elevated ESR, eosinophilia, fever, interstitial nephritis, myalgia, rash, and vasculitis has been reported to be associated with ACE inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1000082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benazepril, any component, or other ACE inhibitors; patients with a history of angioedema (with or without prior ACE inhibitor therapy)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5089234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage reduction may be necessary; avoid rapid dosage escalation which may lead to further renal impairment. Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution when initiating therapy and in volume-depleted patients; may cause symptomatic hypotension with or without syncope, usually with the first several doses; correct volume depletion prior to initiation; initiate lower doses in patients with sodium or volume depletion; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension alone is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation. Use caution in patients with ischemic heart disease or cerebrovascular disease during therapy initiation; observe closely due to the potential consequences posed by falling blood pressure (eg, MI, stroke); fluid replacement may be required to restore blood pressure; therapy may then be resumed; discontinue therapy in patients whose hypotension recurs. Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia. Use with caution in patients with hypertrophic cardiomyopathy (HCM) and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause hyperkalemia; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts; use with caution, if at all, with these agents, and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution before, during, or immediately after major surgery; cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release; use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. In pediatric patients, an isolated dry hacking cough  lasting &gt;3 weeks was reported in seven of 42 pediatric patients (17%) receiving ACE inhibitors (von Vigier, 2000); a review of pediatric randomized-controlled ACE inhibitor trials reported a lower incidence of  3.2%; a higher incidence  of cough has been reported in pediatric patients receiving benazepril (15.2%); however, this may have resulted from differences in study methodology (Baker-Smith, 2010). Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1000083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Angioedema can occur at any time during treatment (especially following first dose). Angioedema may occur in the head, neck, extremities, or intestines; patients with angioedema of the intestines may present with abdominal pain (with or without nausea or vomiting); angioedema of the larynx, glottis, or tongue may cause airway obstruction, especially in patients with a history of airway surgery. Prolonged monitoring may be required, even in patients with swelling of only the tongue (ie, without respiratory distress) because treatment with corticosteroids and antihistamines may not be sufficient; very rare fatalities have occurred with angioedema of the larynx or tongue; appropriate treatment (eg, establishing patent airway and/or SubQ epinephrine) should be readily available for patients with angioedema of larynx, glottis, or tongue, in whom airway obstruction is likely to occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Life-threatening anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Benazepril has been associated with rare but potentially fatal cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia; higher risk for development of neutropenia is associated with renal impairment; risk is further increased in patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus). Onset of neutropenia is usually within 3 months of ACE inhibitor initiation; closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter in these patients; neutrophil count generally returns to baseline within 2 weeks of discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     ACE inhibitor use has been associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs and initiate appropriate medical treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F139550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide: May enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5687403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases the rate, but does not significantly decrease the extent of absorption. Limit salt substitutes or potassium-rich diet. Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F139564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Benazepril crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3424197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure (supervise for at least 2 hours after the initial dose or any dosage increase for significant orthostasis); renal function, WBC, serum potassium; monitor for angioedema and anaphylactoid reactions",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1000097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5089235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Reduction in plasma angiotensin-converting enzyme (ACE) activity: 1-2 hours after 2-20 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Reduction in blood pressure: Single dose: 2-4 hours; Continuous therapy: 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Reduction in plasma angiotensin-converting enzyme (ACE) activity: &gt;90% inhibition for 24 hours after 5-20 mg dose",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1000099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 37%; rapidly absorbed;",
"     <b>",
"      Note:",
"     </b>",
"     Metabolite (benazeprilat) is unsuitable for oral administration due to poor absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~8.7 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Benazepril: 97%; benazeprilat: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly and extensively metabolized (primarily in the liver) to benazeprilat (active metabolite), via cleavage of ester group; extensive first-pass effect. Benazeprilat is about 200 times more potent than benazepril. Parent and active metabolite undergo glucuronide conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Benazeprilat: Terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents 6-16 years: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parent drug: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Active metabolite (benazeprilat):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fasting: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nonfasting: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Hepatic clearance is the main elimination route of unchanged benazepril. Only trace amounts of unchanged benazepril appear in the urine; 20% of dose is excreted in urine as benazeprilat, 8% as benazeprilat glucuronide, and 4% as benazepril glucuronide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Nonrenal excretion (ie, biliary) appears to contribute to the elimination of benazeprilat (11% to 12% in healthy adults); biliary clearance may be increased in patients with severe renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: ~6% of metabolite removed within 4 hours of dialysis following 10 mg of benazepril administered 2 hours prior to procedure; parent compound not found in dialysate",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1000115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/42/2726?source=see_link\">",
"      see \"Benazepril: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician immediately if swelling of face, lips, tongue, or difficulty in breathing occurs; if these occur, do not take any more doses until a physician can be consulted. Notify physician if vomiting, diarrhea, excessive perspiration, dehydration, or persistent cough occurs. Do not add a salt substitute (potassium-containing) without physician advice. May cause dizziness, fainting, and lightheadedness, especially in first week of therapy. Sit and stand up slowly. May cause changes in taste or rash. Report sore throat, fever, other signs of infection, or other side effects. This medication may cause injury and death to the developing fetus when used during pregnancy; women of childbearing potential should be informed of potential risk; consult prescriber for appropriate contraceptive measures;  this medication should be discontinued as soon as possible once pregnancy is detected.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F139559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 2 mg/mL oral suspension may be made with tablets. Mix fifteen benazepril 20 mg tablets in an amber polyethylene terephthalate bottle with Ora-Plus&reg; 75 mL. Shake for 2 minutes, allow suspension to stand for &ge;1 hour, then shake again for at least 1 additional minute. Add Ora-Sweet&reg; 75 mL to suspension and shake to disperse. Will make 150 mL of a 2 mg/mL suspension. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 30 days.",
"    </p>",
"    <div class=\"reference\">",
"     Lotensin&reg; prescribing information, Novartis Pharmaceuticals Corporation, Suffern, NY, 2009.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110:588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker-Smith CM, Benjamin DK Jr, Califf RM, et al, \"Cough in Pediatric Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2010, 87(6):668-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/20130570/pubmed\" id=\"20130570\" target=\"_blank\">",
"        20130570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown NJ, Ray WA, Snowden M, et al, &ldquo;Black Americans Have an Increased Rate of Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(1):8-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/8689816/pubmed\" id=\"8689816\" target=\"_blank\">",
"        8689816",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin PR, Moore TJ, Swartz SL, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Consensus Recommendations for the Management of Chronic Heart Failure. On Behalf of the Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1999, 83(2A):1A-38A.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/10072251/pubmed\" id=\"10072251\" target=\"_blank\">",
"        10072251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Evaluation and Management of Heart Failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1995, 92(9):2764-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/7594057/pubmed\" id=\"7594057\" target=\"_blank\">",
"        7594057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaiser G, Ackermann R, Brechb&uuml;hler S, et al, \"Pharmacokinetics of the Angiotensin Converting Enzyme Inhibitor Benazepril.HCl (CGS 14 824 A) in Healthy Volunteers After Single and Repeated Administration,\"",
"      <i>",
"       Biopharm Drug Dispos",
"      </i>",
"      , 1989, 10(4):365-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/2758102/pubmed\" id=\"2758102\" target=\"_blank\">",
"        2758102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konstam MA, Dracup K, Baker, DW, et al, &ldquo;Heart Failure Evaluation and Care of Patients With Left-Ventricular Systolic Dysfunction,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 1995, 1(2):183-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/9420649/pubmed\" id=\"9420649\" target=\"_blank\">",
"        9420649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(23):2312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/1058733/pubmed\" id=\"1058733\" target=\"_blank\">",
"        1058733",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A, &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Vigier RO, Mozzettini S, Truttmann AC, et al, &ldquo;Cough is Common in Children Prescribed Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Nephron",
"      </i>",
"      , 2000, 84(1):98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/5/40023/abstract-text/10644922/pubmed\" id=\"10644922\" target=\"_blank\">",
"        10644922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12871 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40023=[""].join("\n");
var outline_f39_5_40023=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708641\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139577\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139578\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000076\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000107\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139554\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139541\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5089236\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5687404\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000077\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139619\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139617\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000082\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5089234\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000083\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298824\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139550\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5687403\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139551\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139564\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424197\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000097\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5089235\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000099\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000115\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139559\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12871\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12871|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=related_link\">",
"      Benazepril: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/42/2726?source=related_link\">",
"      Benazepril: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_5_40024="Hepatitis B virus and dialysis patients";
var content_f39_5_40024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatitis B virus and dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/5/40024/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40024/contributors\">",
"     Tak-Mao Chan, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/5/40024/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40024/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40024/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/5/40024/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40024/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/5/40024/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus (HBV) infection can lead to acute or chronic hepatitis, cirrhosis, or hepatocellular carcinoma. Despite the availability of effective vaccines since 1982, HBV infection has remained endemic in many localities, with more than 350 million chronic HBV carriers worldwide. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HBV infection in dialysis patients presents a distinct clinical problem in view of the immunosuppressive effect of renal failure, the susceptibility for de novo infection and nosocomial transmission, the long-term implications on morbidity and mortality, and the change in clinical course after kidney transplantation. The natural history of HBV infection in dialysis patients may also vary according to the timing of infection, genotype, and thus locality.",
"   </p>",
"   <p>",
"    In endemic areas, most adult dialysis patients with HBV infection are chronic carriers who acquired HBV infection during early childhood. By comparison, HBV infection in non-endemic areas is often acquired during adulthood. Dialysis patients are more prone to become chronic carriers compared to patients without renal failure due to their immunosuppressed state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of newly HBV-infected dialysis patients have a relatively mild clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/2\">",
"     2",
"    </a>",
"    ]. Infected patients are often asymptomatic, and have normal or only slightly elevated serum transaminase levels. Data from patients on peritoneal dialysis showed that the impact of HBV infection per se on the survival of dialysis patients was relatively small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, there is a significant risk of clinical deterioration in the HBV infected renal transplant recipient. The risk of severe life-threatening complications is highest when de novo HBV infection occurs shortly after transplantation, but hepatitic flares and liver-related complications can occur at any time after kidney transplantation in HBsAg-positive kidney transplant recipients, including those who have been asymptomatic HBV carriers during dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Therefore, despite the relatively benign clinical disease in dialysis patients, the importance of preventing and treating HBV infection in dialysis patients must be underscored.",
"   </p>",
"   <p>",
"    This topic review will discuss HBV infection among patients with end stage renal disease (ESRD). Reviews of different aspects of HBV infection in patients without renal failure can be found separately (see appropriate topic reviews). Renal disease resulting from HBV infection and the interplay between HBV infection and the renal transplant recipient are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44488?source=see_link\">",
"     \"Renal disease associated with hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/37/1625?source=see_link\">",
"     \"Hepatitis B virus infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HBV infection in dialysis patients has significantly decreased over the past few decades. This is due to the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Screening of blood products for HBsAg and anti-HBc",
"     </li>",
"     <li>",
"      Implementation of infection control measures",
"     </li>",
"     <li>",
"      Reduced need for transfusion after the advent of erythropoietin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis B vaccination (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35959?source=see_link\">",
"       \"Immunizations in patients with end-stage renal disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A national surveillance in the United States in 2002 involving 263,820 patients from 4,035 dialysis centers revealed that 1 percent of dialysis patients were seropositive for HBsAg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/8\">",
"     8",
"    </a>",
"    ]. The annual incidence of HBV infection among dialysis patients, which was 0.12 percent in 2002, has remained relatively stable over the past decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HBsAg positivity rates in dialysis patients correlate with endemicity in the general population, as illustrated by the prevalence rates within Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. HBsAg prevalence rates in dialysis patients have been reported as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1 percent in United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      5.9 percent in Italy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      12 percent in Brazil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      1.3 to 14.6 percent in Asian Pacific countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR HBV INFECTION IN DIALYSIS UNITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent risk factors for HBV infection among dialysis patients in nonendemic areas include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence of HBsAg positive patients within the same dialysis unit",
"     </li>",
"     <li>",
"      Nonsegregation with dedicated hemodialysis machines for HBsAg positive patients",
"     </li>",
"     <li>",
"      A lower than 50 percent prevalence rate of hepatitis B vaccination among dialysis patients in the same unit",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nosocomial transmission is a well-recognized risk for HBV infection in hemodialysis patients. The preparation of injectable medications on a cart or in a location within the hemodialysis treatment area is associated with a higher incidence rate for HBV infection compared to centers that prepared these medications in a dedicated medication room (2002 incidence rates of 0.27 and 0.06 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Prevention of HBV infection in dialysis units'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Even in HBsAg-negative dialysis patients with a history of resolved HBV infection, minute amounts of transcriptionally active HBV DNA could be detected by polymerase chain reaction in peripheral blood mononuclear cells and serum samples from about 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/17\">",
"     17",
"    </a>",
"    ]. This phenomenon was associated with deletions in the pre-S1 region of the viral genome, which affected the S promoter, thereby reducing the production of HBsAg.",
"   </p>",
"   <p>",
"    Crucial to preventing nosocomial transmission are the implementation of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adherence to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Standard or universal precautionary measures",
"     </li>",
"     <li>",
"      Hemodialysis unit procedures for the prevention of blood borne infections",
"     </li>",
"     <li>",
"      Hepatitis B vaccination of nonimmune individuals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Prevention of HBV infection in dialysis units'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Hepatitis B vaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Outbreaks of HBV infection in dialysis units have been attributed to the omission of initial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    periodic HBsAg screening for patients, the sharing of multidose vials or blood-contact equipments, and failure to reduce the susceptible pool of patients by vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/18\">",
"     18",
"    </a>",
"    ]. Although HBV DNA traverses the dialyzer membrane during high flux dialysis, the degree of infectivity of dialysate and ultrafiltrate remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on peritoneal dialysis have a lower risk of acquiring HBV infection compared to those on long-term hemodialysis. There is a reported 19-fold difference in seroconversion rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF HBV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV is a partly double stranded circular DNA virus. The complete infectious virion (Dane particle) consists of a 42 nm spherical envelope carrying the HBsAg, a 27 nm inner shell of nucleocapsid with the hepatitis B core antigen (HBcAg), and a processing derivative hepatitis B e antigen (HBeAg). The viral genome and its tightly associated DNA polymerase are located within the inner nucleocapsid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21045?source=see_link\">",
"     \"Characteristics of the hepatitis B virus and pathogenesis of infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conventional diagnosis of current or past HBV infection is based on immunoassays for HBsAg, anti-HBs, anti-HBc, IgM anti-HBc, HBeAg, and anti-HBe, combinations of which can indicate the stage of infection, viral replication and infectivity, and the immune status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Although seropositivity for HBeAg has often been used as a surrogate marker for viral replication, it is unreliable in infections by precore or core promoter HBV mutants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the serum levels of liver enzymes, which reflect hepatocyte lysis, measurement of HBV DNA in serum provides direct qualitative or quantitative information on viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Quantitative real-time polymerase chain reaction (PCR) assays for HBV DNA offer increased sensitivity with detection threshold down to 20 IU or 10(2)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the majority of dialysis patients, testing for HBsAg is sufficient for the diagnosis of HBV infection. Nevertheless, a negative HBsAg test does not preclude absolutely the presence of occult HBV infection. Occult HBV infection has been defined by positivity in nested PCR assays for the",
"    <span class=\"nowrap\">",
"     pre-S/S,",
"    </span>",
"    <span class=\"nowrap\">",
"     pre-Core/Core,",
"    </span>",
"    and X viral regions with sensitivity down to 10",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    although the level of viremia in patients with occult hepatitis B is generally low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/30\">",
"     30",
"    </a>",
"    ]. One Canadian study screened 241 chronic hemodialysis patients for occult hepatitis B virus infection by HBV DNA testing based upon real-time polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/31\">",
"     31",
"    </a>",
"    ]. Two patients (0.8 percent) were HBsAg positive, while nine (3.8 percent) of the remaining 239 HBsAg negative patients were HBV DNA positive.",
"   </p>",
"   <p>",
"    In patients with chronic HBV infection, determination of",
"    <span class=\"nowrap\">",
"     HBeAg/anti-HBe",
"    </span>",
"    status is indicated in case of hepatitis flare, or when anti-viral treatment is considered. Serial testing of alpha-fetal protein levels is important for the early diagnosis of hepatocellular carcinoma in HBsAg positive patients. Testing for HBV DNA may be indicated in patients with hepatitis who are positive for anti-HBc, but negative for HBsAg, anti-HBs, anti-HCV, and HCV RNA.",
"   </p>",
"   <p>",
"    A detailed discussion concerning the diagnosis and monitoring of HBV infection can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVENTION OF HBV INFECTION IN DIALYSIS UNITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to other blood borne infections, the circulating load of HBV can be high in HBsAg positive individuals, and the virus can survive on environmental surfaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/32\">",
"     32",
"    </a>",
"    ]. Consequently, dialysis patients, in particular those on hemodialysis, are at risk for nosocomial HBV infection. The latter has been related to inadequate infection control measures or technical breaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To prevent nosocomial transmission, standard precautionary measures must be rigorously followed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/35\">",
"     35",
"    </a>",
"    ]. These include barrier procedures to prevent exposure to blood borne microorganisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Washing hands after contact with potentially infectious surface or material",
"     </li>",
"     <li>",
"      Wearing gloves when contacting potentially infectious surface or material",
"     </li>",
"     <li>",
"      Wearing a face mask and gown when exposure to blood or body fluids is expected",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these standard precautions, measures specific to hemodialysis units are also important to prevent nosocomial HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/36\">",
"     36",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wearing gloves before contact with patients or dialysis equipments",
"     </li>",
"     <li>",
"      Routine cleaning and disinfection procedures",
"     </li>",
"     <li>",
"      Prohibition of sharing instruments or medications among patients",
"     </li>",
"     <li>",
"      Preparing and distributing medications from a centralized area",
"     </li>",
"     <li>",
"      Avoiding the use of medication supply carts",
"     </li>",
"     <li>",
"      Regular screening of HBsAg status in non-immune individuals",
"     </li>",
"     <li>",
"      Hepatitis B vaccination of patients and staff",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Hepatitis B vaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of HBV-infected hemodialysis patients with nucleotide or nucleoside analogues may also reduce the risk of other hemodialysis patients in the same center acquiring HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/37\">",
"     37",
"    </a>",
"    ]. This is consistent with the well-established association between the risk of nosocomial transmission and the prevalence of HBsAg positive patients in a hemodialysis center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Segregation and reuse of dialyzers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to segregate and use dedicated hemodialysis machines for HBsAg positive patients is associated with an increased incidence of HBV infection, and machine segregation is now standard practice. On the other hand, the United States national surveillance in 1997 showed no difference in the incidence of HBV infection between centers that practiced segregation of dialysis rooms and those that did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/15,38\">",
"     15,38",
"    </a>",
"    ]. Dialyzer reuse was also not associated with a higher risk of HBV infection both in patients and in staff. Nevertheless, the Centers for Disease Control (CDC) recommended that dialyzers from HBsAg",
"    <strong>",
"     -",
"    </strong>",
"    positive patients be excluded from reuse programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HEPATITIS B VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination is important both to prevent susceptible patients from acquiring HBV and to reduce the pool of HBV infected patients. In a case control study, the risk of HBV infection in hemodialysis patients was reduced by 70 percent after hepatitis B vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/39\">",
"     39",
"    </a>",
"    ]. It is imperative that HBV vaccination be performed early in the course of renal failure in non-immune subjects, since seroconversion response correlates with the level of renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/40\">",
"     40",
"    </a>",
"    ]. Issues surrounding hepatitis B vaccination in dialysis patients are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35959?source=see_link\">",
"     \"Immunizations in patients with end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing during the acute or chronic phases of HBV infection can reveal elevations in the concentration of alanine and aspartate aminotransferase levels (ALT and AST). However, hypotransaminasemia is a well-recognized feature in dialysis patients with or without liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/41\">",
"     41",
"    </a>",
"    ]. Consequently, the normal range of transaminases should be adjusted downwards, otherwise the incidence or severity of clinical liver disease might be underestimated. In this regard, levels of 24",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    and 17",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    have been recommended as the upper limits of normal for AST and ALT, respectively, in dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33381?source=see_link\">",
"     \"Serum enzymes in patients with renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acute infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestation of acute HBV infection in dialysis patients is extremely variable. The majority of dialysis patients with new HBV infection are either asymptomatic or have mild clinical symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/2\">",
"     2",
"    </a>",
"    ]. Serum transaminase levels are either normal or only slightly elevated. This also relates to the lower values of the normal range in these patients. It is not uncommon that the diagnosis of HBV infection is made through regular surveillance testing.",
"   </p>",
"   <p>",
"    The serotype of HBV may affect the severity of clinical manifestations. As an example, an outbreak of fulminant hepatitis resulting in four mortalities in a dialysis center in Tokyo was attributed to infection by a precore mutant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute hepatitis B in dialysis patients is more likely to result in chronic infection compared to non-immunosuppressed individuals. Up to 80 percent of acutely infected dialysis patients may become chronic carriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chronic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations of chronic hepatitis B or HBV-induced cirrhosis in dialysis patients are identical to those without renal failure. Aminotransferase levels indicate hepatitic activity, but need to be interpreted according to the adjusted normal ranges. The level of gamma glutamyltranspeptidase may be increased, which could signify bile duct injury. Progression of liver disease manifests as hypoalbuminemia, coagulopathy, and development of complications such as hypersplenism, ascites, esophageal varices, or hepatic encephalopathy. Considerations for combined liver and renal transplantation may be warranted in dialysis patients with severe irreversible liver disease. Co-infection with the hepatitis D virus can lead to more severe liver disease, and needs to be investigated when clinically indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15543?source=see_link\">",
"     \"Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been few studies on the histological manifestations of chronic hepatitis B in dialysis patients, particularly related to its long-term evolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Liver pathology, such as piecemeal necrosis, portal inflammation or fibrosis, is similar to patients without renal failure.",
"   </p>",
"   <p>",
"    Data from the era prior to the advent of nucleoside(tide) analogues suggested inferior clinical outcomes in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the majority of data has not revealed significant differences in morbidity and mortality between dialysis patients who are positive or negative for HBsAg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/45\">",
"     45",
"    </a>",
"    ]. Although histological evidence of chronic hepatitis has been observed in approximately 30 percent of dialysis patients with chronic HBV infection, less than 5 percent of these patients die from liver disease.",
"   </p>",
"   <p>",
"    Factors that may explain this apparent discrepancy include insufficient duration of follow-up and co-morbidities with a considerable adverse impact on patient survival thereby masking the detrimental effects of HBV infection. Examples of the latter include cardiovascular or cerebrovascular complications and infection, which are major causes of death in the dialysis population.",
"   </p>",
"   <p>",
"    Cirrhosis has been associated with a 35 percent increase in mortality rate among dialysis patients; however, whether HBV infection alone has an adverse effect on patient survival remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Before the advent of nucleoside or nucleotide anti-viral medications, the prognostic impact of HBV infection was even worse in renal allograft recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/7,48,49\">",
"     7,48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis patients with chronic HBV infection should have regular monitoring of parenchymal and ductal liver enzymes, and serum albumin concentration, preferably at six to eight week intervals. Prothrombin time should also be measured when there is evidence of severe hepatitis or cirrhosis. In addition, serum alpha-fetal protein levels should be measured every three to four months and liver ultrasound performed at least annually.",
"   </p>",
"   <p>",
"    Since the biochemical manifestations often cannot reliably indicate the status of liver histology, it would be ideal if a liver biopsy is available to best assess the activity of HBV related liver disease and the extent of cirrhotic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/43,50\">",
"     43,50",
"    </a>",
"    ]. However, the role and optimal timing of liver biopsy in otherwise asymptomatic patients without clinical or biochemical abnormalities remain to be defined. Decisions on management for an individual patient must also take into consideration the level of HBV DNA in serum and the estimated waiting time before a kidney allograft is available.",
"   </p>",
"   <p>",
"    For practical purposes, liver biopsy is recommended when anti-viral treatment is being considered. Availability of histological information is also preferred before kidney transplantation, to ascertain the activity of hepatitis and the degree of cirrhosis. However, while it is easy to arrange liver biopsy before living-donor kidney transplantation, the optimal timing for this procedure may be difficult to establish in localities with a long waiting time for transplantation. The role of liver stiffness measurement using transient elastography in patients with renal failure remains to be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions on the treatment of chronic HBV infection are based in part upon an accurate assessment of the presence or absence of virus replication and active liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/51\">",
"     51",
"    </a>",
"    ]. As previously mentioned, this usually involves testing for HBV DNA and HBeAg, measuring the serum ALT concentration, with or without a liver biopsy. Treatment is often indicated when abnormal ALT levels suggest evidence of hepatic inflammation and HBV DNA levels are 4 to 5 log10",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    or above. Based upon these and other clinical findings, optimal therapy may involve the administration of interferon-alfa, nucleoside or nucleotide analogues, combination therapy, liver transplantation, or only observation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A paucity of data exists concerning the optimal therapy of chronic HBV infection in dialysis patients. A few small studies have examined the use of interferon-alfa and nucleoside or nucleotide analogues in this patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Interferon-alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are little data on interferon-alfa treatment in dialysis patients with HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/12\">",
"     12",
"    </a>",
"    ]. Improvement in liver biochemistry and HBe seroconversion was observed in two patients after treatment with 3 MU of interferon-alfa thrice weekly for three months, with follow-up durations of nine months and four years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to patients without renal failure, in whom interferon-alfa therapy is generally well tolerated, the side effects of",
"    <strong>",
"     standard",
"    </strong>",
"    interferon-alfa are more pronounced in dialysis patients, especially with regard to the exacerbation of anemia and protein malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Preliminary data suggest that pegylated interferon might be better tolerated in patients with renal failure, although its efficacy and safety in hepatitis B treatment in this patient population remains undefined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/55\">",
"     55",
"    </a>",
"    ]. A discussion of the details concerning the side effects of interferon-alpha in dialysis patients can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31114?source=see_link\">",
"     \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Nucleoside or nucleotide analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    is the (-)-enantiomer of 3'-thiacytidine, an oral nucleoside analogue that interferes with the reverse transcriptase of HBV and terminates the nascent proviral DNA. It is the first in this class of drugs approved for the treatment of hepatitis B. Its safety and lack of significant adverse effects relate to the sparing of mitochondrial DNA and marrow progenitor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/56\">",
"     56",
"    </a>",
"    ]. In nonimmunosuppressed individuals without renal dysfunction, lamivudine has proven efficacy in reducing the level of circulating HBV DNA, improving transaminasemia, and ameliorating hepatic necroinflammatory activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/26,57\">",
"     26,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is also effective in dialysis patients and renal allograft recipients, resulting in the suppression of viral replication and aminotransferase normalization in more than 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/12,26,49,58-63\">",
"     12,26,49,58-63",
"    </a>",
"    ]. After treatment durations lasting 10 to 14 months, lamivudine therapy cleared HBeAg in over 20 percent of patients, and suppressed HBV DNA to undetectable levels in 50 to 100 percent. There is little information on histological changes after treatment in dialysis patients.",
"   </p>",
"   <p>",
"    However, the selection of drug-resistant variants after prolonged treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    presents a major limitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/58,64,65\">",
"     58,64,65",
"    </a>",
"    ]. Such resistance, occurring in around 15 percent of patients after 12 months, more than 30 percent after two years, and over half of patients after three years of lamivudine therapy, is almost universally associated with mutations in the highly conserved YMDD (tyrosine, methionine, aspartate, aspartate) nucleotide-binding motif of the major catalytic domain of the HBV RNA dependent DNA polymerase. The emergence of lamivudine resistance can be associated with potentially life-threatening exacerbation of liver disease. Lamivudine is no longer regarded as the preferred first-line therapy for hepatitis B. In patients without renal disease,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    are the recommended first-line oral medications for hepatitis B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/66\">",
"     66",
"    </a>",
"    ]. It should be noted that tenofovir, similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    , can lead to renal tubular dysfunction and nephrotoxicity.",
"   </p>",
"   <p>",
"    Many patients have been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and have developed drug resistance. For the management of these patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    add-on therapy has been associated with a high response rate and a lower rate of subsequent resistance compared with switching to adefovir monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    can also be an effective alternative in patients with lamivudine-resistant HBV infection, and has greater antiviral activity compared with adefovir. However, both adefovir and tenofovir are nephrotoxic, and are preferably avoided in dialysis patients with residual renal function, because the latter confers survival benefit. Switching lamivudine to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    monotherapy is also effective in viral suppression, but progressive emergence of entecavir resistance with prolonged treatment could pose a problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40024/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Entecavir is the recommended first-line oral therapy in patients with kidney diseases. The doses of all medications must be adjusted appropriately in patients with end-stage renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23030?source=see_link\">",
"     \"Investigational treatments of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is recommended that effective treatment be started early after the emergence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance, both to prevent hepatitic flares and to reduce the risk of subsequent development of multiple drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis B virus (HBV) infection can lead to acute or chronic hepatitis, cirrhosis, or hepatocellular carcinoma. HBV infection in dialysis patients presents a distinct clinical problem in view of the immunosuppressive effect of renal failure, the susceptibility for de novo infection and nosocomial transmission, the long-term implications on morbidity and mortality, and the change in clinical course after kidney transplantation. The natural history of HBV infection in dialysis patients may also vary according to the timing of infection and genotype. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis patients are at increased risk of contracting hepatitis B due to nosocomial transmission. Prevention of HBV infection through universal precautions and vaccination are of critical importance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors for HBV infection in dialysis units'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Prevention of HBV infection in dialysis units'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the majority of dialysis patients, testing for HBsAg is sufficient for the diagnosis of HBV infection. Nevertheless, a negative HBsAg test does not preclude absolutely the presence of occult HBV infection. Occult HBV infection has been defined by positivity in nested PCR assays for the",
"      <span class=\"nowrap\">",
"       pre-S/S,",
"      </span>",
"      <span class=\"nowrap\">",
"       pre-Core/Core,",
"      </span>",
"      and X viral regions with sensitivity down to 10",
"      <span class=\"nowrap\">",
"       copies/mL,",
"      </span>",
"      although the level of viremia in patients with occult hepatitis B is generally low. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis of HBV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The manifestations of acute HBV infection in dialysis patients are variable. The manifestations of chronic hepatitis B or HBV-induced cirrhosis in dialysis patients are identical to those without renal failure. Aminotransferase levels indicate hepatitic activity, but need to be interpreted according to the adjusted normal range, which is lower in patients on long-term dialysis. Hepatitis B infection leads to liver complications and reduces the survival of kidney transplant recipients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the clinical course of HBV infection in dialysis patients appears less severe, the aim of management is to minimize the progression of liver disease and for the early detection of liver complications including hepatocellular carcinoma. Treatment is indicated in HBsAg-positive patients with evidence of disease activity, as indicated by viral replication and abnormal transaminase levels, preferably corroborated by examination of liver histology. A level of 4 to 5 log10",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      for HBV DNA is usually taken as the threshold to start treatment. With the advent of more sensitive quantitative assays, it remains to be investigated whether the treatment level needs to be adjusted downwards. It is important to realize that HBeAg can be negative in patients with precore- or core promotor-mutant infection despite active disease. In view of the side effects of interferon in patients on dialysis, nucleotide or nucleoside analogues are better choices;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      is the recommended first-line oral therapy in patients with kidney diseases. The doses of all medications must be adjusted appropriately in patients with end-stage renal disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Overview of management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/1\">",
"      Ribot S, Rothstein M, Goldblat M, Grasso M. Duration of hepatitis B surface antigenemia (HBs Ag) in hemodialysis patients. Arch Intern Med 1979; 139:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/2\">",
"      Harnett JD, Parfrey PS, Kennedy M, et al. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis 1988; 11:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/3\">",
"      Chow KM, Szeto CC, Wu AK, et al. Continuous ambulatory peritoneal dialysis in patients with hepatitis B liver disease. Perit Dial Int 2006; 26:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/4\">",
"      Friedlaender MM, Kaspa RT, Rubinger D, et al. Renal transplantation is not contraindicated in asymptomatic carriers of hepatitis B surface antigen. Am J Kidney Dis 1989; 14:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/5\">",
"      Pirson Y, Alexandre GP, Ypersele C. Long-term effect of hbs antigenemia on patient survival after renal transplantation. N Engl J Med 1977; 296:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/6\">",
"      Weir MR, Kirkman RL, Strom TB, Tilney NL. Liver disease in recipients of long-functioning renal allografts. Kidney Int 1985; 28:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/7\">",
"      Parfrey PS, Forbes RD, Hutchinson TA, et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 1985; 39:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/8\">",
"      Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/9\">",
"      Oguchi H, Miyasaka M, Tokunaga S, et al. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992; 38:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/10\">",
"      Chan TM, Lok AS, Cheng IK. Hepatitis C infection among dialysis patients: a comparison between patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991; 6:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/11\">",
"      Johnson DW, Dent H, Yao Q, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant 2009; 24:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/12\">",
"      Fabrizi, F, Martin, P. Management of hepatitis B and C virus infection before and after renal transplantation. Curr Opin Organ Transplant 2006; 11:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/13\">",
"      Mioli VA, Balestra E, Bibiano L, et al. Epidemiology of viral hepatitis in dialysis centers: a national survey. Nephron 1992; 61:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/14\">",
"      Teles SA, Martins RM, Vanderborght B, et al. Hepatitis B virus: genotypes and subtypes in Brazilian hemodialysis patients. Artif Organs 1999; 23:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/15\">",
"      Tokars JI, Alter MJ, Miller E, et al. National surveillance of dialysis associated diseases in the United States--1994. ASAIO J 1997; 43:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/16\">",
"      Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003; 63:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/17\">",
"      Cabrerizo M, Bartolom&eacute; J, Caramelo C, et al. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000; 32:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks of hepatitis B virus infection among hemodialysis patients-- California, Nebraska, and Texas, 1994. MMWR Morb Mortal Wkly Rep 1996; 45:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/19\">",
"      Andrew R, Hariharan S, Saha V, et al. Biochemical evaluation of ultrafiltrate in dialysis-dependent HBsAG-positive patients. Nephron 1988; 49:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/20\">",
"      Kroes AC, van Bommel EF, Niesters HG, Weimar W. Hepatitis B viral DNA detectable in dialysate. Nephron 1994; 67:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/21\">",
"      Cendoroglo Neto M, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/22\">",
"      Hoofnagle JH, Waggoner JG. Hepatitis A and B virus markers in immune serum globulin. Gastroenterology 1980; 78:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/23\">",
"      Miller RH, Kaneko S, Chung CT, et al. Compact organization of the hepatitis B virus genome. Hepatology 1989; 9:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/24\">",
"      Blum HE. Hepatitis B virus: significance of naturally occurring mutants. Intervirology 1993; 35:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/25\">",
"      Chan TM, Wu PC, Li FK, et al. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/26\">",
"      Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/27\">",
"      Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/28\">",
"      Paraskevis D, Haida C, Tassopoulos N, et al. Development and assessment of a novel real-time PCR assay for quantitation of HBV DNA. J Virol Methods 2002; 103:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/29\">",
"      Ho SK, Yam WC, Leung ET, et al. Rapid quantification of hepatitis B virus DNA by real-time PCR using fluorescent hybridization probes. J Med Microbiol 2003; 52:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/30\">",
"      Hui CK, Sun J, Au WY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/31\">",
"      Minuk GY, Sun DF, Greenberg R, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004; 40:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/32\">",
"      Favero MS, Bond WW, Petersen NJ, et al. Detection methods for study of the stability of hepatitis B antigen on surfaces. J Infect Dis 1974; 129:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/33\">",
"      Niu, MT, Penberthy, LT, Alter, MJ, et al. Hemodialysis-associated hepatitis B: report of an outbreak. Dial Transplant 1989; 18:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/34\">",
"      Alter MJ, Ahtone J, Maynard JE. Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. Ann Intern Med 1983; 99:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/35\">",
"      Kellerman S, Alter MJ. Preventing hepatitis B and hepatitis C virus infections in end-stage renal disease patients: back to basics. Hepatology 1999; 29:291.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control: Control measures for hepatitis B in dialysis centers. Viral hepatitis Investigations and Control Series, Atlanta. Centers for Disease Control and Prevention, 1977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/37\">",
"      Goodkin DA, Young EW, Kurokawa K, et al. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004; 44:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/38\">",
"      Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial 2004; 17:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/39\">",
"      Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999; 33:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/40\">",
"      DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 42:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/41\">",
"      Yasuda K, Okuda K, Endo N, et al. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology 1995; 109:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/42\">",
"      Tanaka S, Yoshiba M, Iino S, et al. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. Kidney Int 1995; 48:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/43\">",
"      Degott C, Degos F, Jungers P, et al. Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver 1983; 3:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/44\">",
"      Coughlin GP, Van Deth AG, Disney AP, et al. Liver disease and the e antigen in HBsAg carriers with chronic renal failure. Gut 1980; 21:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/45\">",
"      Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis 1987; 9:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/46\">",
"      Held PJ, Port FK, Turenne MN, et al. Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of patient mortality with adjustment for comorbid conditions. Kidney Int 1994; 45:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/47\">",
"      Jha, R, Kher, V, Naik, S, et al. Hepatitis B associated liver disease in dialysis patients: role of vaccination. J Nephrol 1993; 6:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/48\">",
"      Harnett JD, Zeldis JB, Parfrey PS, et al. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 1987; 44:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/49\">",
"      Chan TM, Fang GX, Tang CS, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/50\">",
"      Ozdo��an M, Ozg&uuml;r O, G&uuml;r G, et al. Histopathological impacts of hepatitis virus infection in hemodialysis patients: should liver biopsy be performed before renal transplantation? Artif Organs 1997; 21:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/51\">",
"      Fehr T, Amb&uuml;hl PM. Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant 2004; 19:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/52\">",
"      Duarte R, Huraib S, Said R, et al. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis 1995; 25:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/53\">",
"      Chan TM, Wu PC, Lau JY, et al. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997; 12:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/54\">",
"      Campistol JM, Esforzado N, Mart&iacute;nez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14:2704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/55\">",
"      Chan TM, Ho SK, Tang CS, et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton) 2007; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/56\">",
"      Regev A, Schiff ER. Drug therapy for hepatitis B. Adv Intern Med 2001; 46:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/57\">",
"      Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/58\">",
"      Fontaine H, Thiers V, Chr&eacute;tien Y, et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/59\">",
"      Girndt M, K&ouml;hler H. Hepatitis B virus infection in hemodialysis patients. Semin Nephrol 2002; 22:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/60\">",
"      Boyacioglu S, G&uuml;r G, G&uuml;rsoy M, Ozdemir N. Lamivudine in renal transplant candidates with chronic hepatitis B infection. Transplant Proc 2002; 34:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/61\">",
"      Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, Ben-Ari Z. Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol 2003; 37:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/62\">",
"      Lapinski TW, Flisiak R, Jaroszewicz J, et al. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol 2005; 11:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/63\">",
"      Yap DY, Tang CS, Yung S, et al. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010; 90:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/64\">",
"      Kletzmayr J, Watschinger B, M&uuml;ller C, et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000; 70:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/65\">",
"      Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/66\">",
"      Jafri SM, Lok AS. Antiviral therapy for chronic hepatitis B. Clin Liver Dis 2010; 14:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/67\">",
"      Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/68\">",
"      Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/69\">",
"      de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001; 34:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40024/abstract/70\">",
"      Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129:1198.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1931 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40024=[""].join("\n");
var outline_f39_5_40024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS FOR HBV INFECTION IN DIALYSIS UNITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS OF HBV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVENTION OF HBV INFECTION IN DIALYSIS UNITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Segregation and reuse of dialyzers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HEPATITIS B VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acute infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chronic infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Interferon-alfa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Nucleoside or nucleotide analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21045?source=related_link\">",
"      Characteristics of the hepatitis B virus and pathogenesis of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/37/1625?source=related_link\">",
"      Hepatitis B virus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31114?source=related_link\">",
"      Hepatitis C virus infection in patients on maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35959?source=related_link\">",
"      Immunizations in patients with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23030?source=related_link\">",
"      Investigational treatments of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15543?source=related_link\">",
"      Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33381?source=related_link\">",
"      Serum enzymes in patients with renal failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_5_40025="Surgical management of complications of peptic ulcer disease";
var content_f39_5_40025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical management of complications of peptic ulcer disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/5/40025/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40025/contributors\">",
"     Stephen J Ferzoco, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40025/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/5/40025/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40025/contributors\">",
"     David I Soybel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40025/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/5/40025/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/5/40025/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/5/40025/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major complications of peptic ulcer disease include bleeding, perforation, penetration, and gastric outlet obstruction. Although a history of preceding ulcer symptoms is common, many patients have no preceding typical peptic ulcer symptoms or known disease. The role of surgery in the management of these complications is reviewed here. The role of elective surgery in peptic ulcer disease and the medical management of peptic ulcer complications are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33688?source=see_link\">",
"     \"Role of surgery in the management of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40282?source=see_link\">",
"     \"Overview of the complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6861940\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been significant declines in the incidence of hospitalization for peptic ulcer disease (PUD) since 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the Healthcare Cost and Utilization Project Nationwide Inpatient Sample hospitalizations for PUD decreased 30 percent from 1993 to 2006, with the decline being greater for duodenal than gastric ulcers (37 versus 20 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/2\">",
"     2",
"    </a>",
"    ]. These changes have been attributed to better medical therapy, including proton pump inhibitors and regimens for eradication of Helicobacter pylori (H. pylori). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=see_link\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemorrhage was the most common complication of PUD (73 percent) in this study, followed by perforation (9 percent), and obstruction (3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/2\">",
"     2",
"    </a>",
"    ]. The mortality from associated complications of PUD was more than 10 times that of acute appendicitis or acute cholecystitis. Perforation had the highest mortality rate, followed by obstruction and hemorrhage.",
"   </p>",
"   <p>",
"    Because of the decrease in the hospitalization rate for PUD, surgeons now have considerably less experience with the management of complications of ulcer disease and more technically demanding procedures such as parietal cell or highly selective vagotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493276269\">",
"    <span class=\"h1\">",
"     UNDERLYING CAUSES OF PEPTIC ULCER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of complicated PUD is characterized by recurrent complications, unless the underlying cause can be reversed. H. pylori, NSAIDs, and use of low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    are the most prominent causes of ulcer bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/5\">",
"     5",
"    </a>",
"    ] and ulcer perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. However, complications can also occur in non-H. pylori, non-NSAID ulcers. The causes of PUD are discussed below. The natural history of PUD and recurrent ulcer disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16345?source=see_link\">",
"     \"Refractory or recurrent peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6862161\">",
"    <span class=\"h1\">",
"     SURGICAL CONSULTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of early medical-surgical collaboration for all patients with ulcer complications cannot be overemphasized. In addition to aiding in the resuscitation of the unstable patient, collaboration between the gastroenterologist, the intensivist, and the surgeon permits the establishment of goals and limits for initial nonoperative therapy. Early consultation also allows more time for preoperative preparation and evaluation, and for education of patients and families should urgent surgical intervention become necessary.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    If surgery is indicated, it should be done promptly, as soon as the indication is established and the patient is appropriately resuscitated. Excellent results are possible with well coordinated, skilled, timely decision-making and implementation. As an example, there were no deaths in an observational study of 66 high risk patients who received urgent surgery for peptic ulcer bleeding associated with shock on admission, age &gt;65 years, an ulcer size &gt;2 cm, or a history of prior gastric surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urgent surgery is required in patients with uncontrolled hemorrhage and perforated ulcer with continued leakage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/10\">",
"     10",
"    </a>",
"    ]. The particular surgical intervention employed for various complications of peptic ulcers depends on the complication, ulcer location and characteristics, and the patient's overall status. The management of bleeding ulcers, perforated ulcers, penetrating ulcers, and gastric outlet obstruction are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274237\">",
"    <span class=\"h1\">",
"     BLEEDING ULCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper gastrointestinal (UGI) bleeding secondary to peptic ulcer is a common medical condition that results in high morbidity and medical care costs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274244\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with bleeding ulcers can be managed acutely with fluid and blood resuscitation, acid antisecretory therapy, and endoscopic intervention, as appropriate. Early intravenous IV proton pump inhibitor (PPI) treatment promotes rapid healing and reduces rebleeding rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/11\">",
"     11",
"    </a>",
"    ]. Starting intravenous PPI therapy before endoscopy decreases the rate of active bleeding and the need for endoscopic treatment. Endoscopic therapy using contact thermal devices, endoscopic hemoclips,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    combination therapy with epinephrine injection will control bleeding in the majority of patients.",
"   </p>",
"   <p>",
"    Active bleeding at presentation, hematemesis, rebleeding, and the need for surgery predict increased overall risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/12\">",
"     12",
"    </a>",
"    ]. Certain factors predict failure of endoscopic therapy, such as hypotension and ulcers larger than 2 cm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Endoscopic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=see_link&amp;anchor=H57224540#H57224540\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Acid suppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274251\">",
"    <span class=\"h2\">",
"     Indications for surgery for a bleeding ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delaying surgery for high risk patients compromises outcomes. Prolonged resuscitation, large volume transfusion, and periods of hypotension are poorly tolerated in high risk patients. Surgery for peptic ulcer hemorrhage is indicated in the following circumstances (",
"    <a class=\"graphic graphic_table graphicRef62297 \" href=\"mobipreview.htm?9/45/9949\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure of endoscopic techniques to arrest hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic instability despite vigorous resuscitation (eg, a &gt;6 unit transfusion during the first 24 hours) in the face of continued bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent hemorrhage, especially with hypotension, after a second attempt at endoscopic hemostasis. Repeat endoscopy is suggested in most cases of rebleeding because a second attempt has a reasonable chance of success and lower risk than surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/13\">",
"       13",
"      </a>",
"      ]. However, if two attempts have failed to achieve prolonged hemostasis, additional attempts at endoscopy are unlikely to be successful.",
"     </li>",
"     <li>",
"      Continued slow bleeding with a transfusion requirement exceeding three units per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Secondary or relative indications include rare blood type or difficult crossmatch, or refusal of transfusion. Giant ulcers, very rapid bleeding rates, shock on presentation, advanced age, and severe comorbid disease are also relative indications for early surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274258\">",
"    <span class=\"h3\">",
"     Bleeding duodenal ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is referred for surgery if the bleeding persists or rebleeding occurs after two therapeutic endoscopies. (See",
"    <a class=\"local\" href=\"#H493274251\">",
"     'Indications for surgery for a bleeding ulcer'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients at high risk for surgery, transcatheter",
"    <span class=\"nowrap\">",
"     arteriography/intervention",
"    </span>",
"    should be considered when endoscopic hemostasis fails. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Treatment of persistent and recurrent bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first priority during emergency surgery for a bleeding ulcer is control of the bleeding site. If endoscopy has failed to precisely identify the source of hemorrhage and the patient proceeds to surgery, the proximal duodenum is opened and inspected for the bleeding vessel. A pyloroduodenotomy may be necessary to inspect the duodenal bulb and gastric antrum. Control is obtained by suture ligature of the bleeding vessel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by ligating the gastroduodenal artery at the superior and inferior aspect of the ulcer. Closure with a pyloroplasty and a truncal vagotomy are performed most frequently.",
"   </p>",
"   <p>",
"    A parietal cell vagotomy (PCV) is a more complex procedure than a truncal vagotomy. Performance of a PCV divides vagal branches to the acid-secreting portion of the stomach but preserves innervation to the antrum and thus gastric emptying. This procedure may represent better therapy for the stable patient who has had a duodenotomy alone, although the benefits of PCV may be abrogated if the pylorus has been divided (pyloroduodenotomy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although control of bleeding without an acid-reducing procedure may be considered in patients with H. pylori who have not yet been treated, this approach has not been evaluated. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274265\">",
"    <span class=\"h3\">",
"     Bleeding gastric ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric resection with Billroth I or II reconstruction (",
"    <a class=\"graphic graphic_figure graphicRef60974 \" href=\"mobipreview.htm?15/7/15475\">",
"     figure 1",
"    </a>",
"    ) is generally indicated for bleeding gastric ulcers because of the risk that the ulcer is malignant. Ulcer excision alone is associated with rebleeding in as many as 20 percent of patients, and thus distal gastrectomy is generally preferred, although ulcer excision combined with truncal vagotomy and pyloroplasty may be considered in high risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33688?source=see_link&amp;anchor=H19#H19\">",
"     \"Role of surgery in the management of peptic ulcer disease\", section on 'Operation for gastric ulcer'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274985\">",
"    <span class=\"h1\">",
"     PERFORATED ULCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duodenal,",
"    <span class=\"nowrap\">",
"     antral/pyloric,",
"    </span>",
"    and gastric body ulcers account for 60, 20, and 20 percent of perforations due to peptic ulcer, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274992\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcer perforation should be suspected in patients with a history of peptic ulcer symptoms who develop the sudden onset of severe, diffuse abdominal pain. Rapid diagnosis is essential since the prognosis is excellent within the first six hours, but deteriorates with more than a 12-hour delay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The history and physical examination provide essential clues; perforation is largely a clinical diagnosis. The following three phases have been described when there is free perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first phase (within two hours of onset), abdominal pain is usually sudden, sometimes producing collapse or even syncope. Localization is usually epigastric at onset, but it quickly becomes generalized. This catastrophic onset reflects bathing of the peritoneal cavity with acidic fluid that probably releases vasoactive mediators which underlie the physiologic response. Tachycardia, a weak pulse, cool extremities, and a low temperature are characteristic features. The first phase may last only a few minutes or up to two hours. The severity of symptoms depends upon how much fluid is released. Pain may radiate to the top of the right shoulder or to both shoulders. Abdominal rigidity begins to develop.",
"     </li>",
"     <li>",
"      In the second phase (2 to 12 hours after onset), abdominal pain may lessen and an inexperienced observer may be led to believe that the patient is getting better. Pain is usually generalized, and is often markedly worse upon movement. The abdomen consistently displays marked board-like rigidity. There may be obliteration of liver dullness to percussion due to peritoneal air. The pelvic peritoneum, palpated at rectal examination, is often tender due to irritation from collected inflammatory fluid. Right lower quadrant tenderness may develop from fluid moving down the gutter.",
"     </li>",
"     <li>",
"      In the third phase (&gt;12 hours after onset), increasing abdominal distention is noted, but abdominal pain, tenderness, and rigidity may be less evident. Temperature elevation and hypovolemia due to third-spacing develop. Acute cardiovascular collapse may occur as peritonitis advances. Persisting or advancing signs of peritonitis and a preoperative delay greater than 12 hours increase the risk of morbidity and mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/21-25\">",
"       21-25",
"      </a>",
"      ]. Perforated gastric ulcers appear to have a poorer prognosis than duodenal ulcers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the perforation is walled off or the fluid is confined by fibrosis, the symptoms may be much less severe and these phases may not be apparent. Posterior perforation provides another situation where symptoms are less dramatic. Compared to free perforations, the upper abdominal pain is more insidious, the presentation often delayed, and the abdominal examination frequently equivocal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274999\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of free air is highly suggestive of perforated duodenal ulcer (DU) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78491 \" href=\"mobipreview.htm?18/12/18639\">",
"     image 1",
"    </a>",
"    ), although about 10 to 20 percent of patients with a perforated DU will not have free air [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Plain x-rays",
"      </strong>",
"      &ndash; An upright chest film and abdominal films should be examined for free air. Careful interpretation can detect diagnostic free air in most cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/27\">",
"       27",
"      </a>",
"      ]. If free air is found, no additional diagnostic studies are necessary.",
"     </li>",
"     <li>",
"      <strong>",
"       Abdominal computed tomography (CT)",
"      </strong>",
"      &ndash; When there is no free air on the plain film and diagnostic uncertainty persists, a high resolution CT should be performed using water soluble oral contrast and carefully examined for free air or fluid, mucosal disease, local inflammation such as fat stranding, and evidence of contrast extravasation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78491 \" href=\"mobipreview.htm?18/12/18639\">",
"       image 1",
"      </a>",
"      ). In a small proportion of cases, fluid (ascites) will be the only clue indicating perforation on imaging studies and rare cases will have neither free air nor fluid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/27\">",
"       27",
"      </a>",
"      ]. Spiral and multidetector-row CTs, especially 64 slice scanners, allow the entire abdomen to be examined on a single breath-hold and improve detection of small amounts of air as well as indirect findings such as free fluid, phlegmon, abscess, bowel wall pathology, and adjacent inflammation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70824 \" href=\"mobipreview.htm?16/59/17331\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Contrast study",
"      </strong>",
"      &ndash; If a CT is not available or is not needed for clinical diagnosis, a carefully performed gastroduodenogram using water soluble contrast is likely to detect most macro-leaks (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57603 \" href=\"mobipreview.htm?21/30/21999\">",
"       image 3",
"      </a>",
"      ). Leakage of water soluble contrast (Gastrografin) is a useful confirmatory test. However, many perforations have already sealed spontaneously by the time of presentation, so that the absence of a leak does not exclude the diagnosis of a perforated ulcer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493275006\">",
"    <span class=\"h2\">",
"     Early management of perforated ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of an ulcer perforation has been made (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78491 \" href=\"mobipreview.htm?18/12/18639\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70824 \" href=\"mobipreview.htm?16/59/17331\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81661 \" href=\"mobipreview.htm?9/34/9762\">",
"     image 4",
"    </a>",
"    ), initial management includes insertion of a nasogastric tube, intravenous volume replacement, treatment with an intravenous proton pump inhibitor (PPI), and broad spectrum intravenous antibiotics. If the H. pylori status is unknown, testing should be done. A decision is then made about whether the patient requires surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40282?source=see_link&amp;anchor=H66923472#H66923472\">",
"     \"Overview of the complications of peptic ulcer disease\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493275028\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antibiotic regimen for a patient with a perforated ulcer should cover enteric gram negative rods, anaerobes, and mouth flora. The antimicrobial susceptibility patterns for gram negative rods such as Escherichia coli (E. coli) have changed with increasing resistance to antibiotics, including fluoroquinolones. Thus, knowledge of local and regional susceptibility patterns for Enterobacteriaceae is essential in selecting empiric therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].&nbsp;",
"   </p>",
"   <p>",
"    Reasonable choices for initial empiric antibiotic therapy in the setting of perforated ulcer consist of either a combination beta",
"    <span class=\"nowrap\">",
"     lactam/beta",
"    </span>",
"    lactamase inhibitor (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    , ticarcillin-clavulanic acid, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ), or a combination of a third-generation cephalosporin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . In areas where local prevalence of extended spectrum beta-lactamase (ESBL) producing organisms and pathogenic E. coli is common, empiric monotherapy with a carbapenem such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    , imipenem, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37960?source=see_link\">",
"     \"Pathogenic Escherichia coli\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of administering an appropriate initial empiric antibiotic regimen was illustrated in a review of 425 patients who required surgery for community-acquired secondary peritonitis, including patients with perforated peptic ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/34\">",
"     34",
"    </a>",
"    ]. In 13 percent of patients, the initial antibiotic regimen was inappropriate, defined as not covering all bacteria subsequently isolated or not covering both aerobic and anaerobic organisms in the absence of culture results. Resolution of the infection after primary surgery was significantly less likely with an inappropriate antibiotic regimen (53 versus 79 percent) and failure to achieve clinical success was associated with a six-day prolongation in hospitalization (20 versus 14 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493275520\">",
"    <span class=\"h2\">",
"     Surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;After resuscitation, emergent operation and closure with a piece of omentum (Graham patch) is the standard of care for patients with an acute perforation.",
"   </p>",
"   <p>",
"    Prolonged efforts to establish a diagnosis or pursue nonoperative care despite worsening status can be counterproductive, since a needed operation will be delayed. Although some patients will seal their perforated ulcers without operation, such an approach has been associated with a prohibitive morbidity and mortality particularly in elderly, high risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40282?source=see_link\">",
"     \"Overview of the complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Duodenal ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforated duodenal ulcers are generally treated by closure with a piece of omentum (Graham patch) or by truncal vagotomy with pyloroplasty (incorporating the perforation). Both approaches are simple and expedient, and the results have generally been good [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/36-40\">",
"     36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simple patch closure of the perforation should be considered in the setting of ongoing shock, delayed presentation, considerable comorbid disease, or marked peritoneal contamination. It is also the simplest procedure for the inexperienced surgeon. Patch closure may also be appropriate for patients who have never been treated for peptic ulcer disease and who can be given PPIs and antibiotic therapy for H. pylori [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/6,41\">",
"     6,41",
"    </a>",
"    ]. NSAID-related perforation can generally be treated with simple closure if the drug can be discontinued postoperatively.",
"   </p>",
"   <p>",
"    Definitive ulcer surgery with an acid-reducing procedure may be desirable in patients in whom the risk of PUD cannot be reliably reduced (such as patients who will require continued use of an NSAID or those who would be unlikely to comply with H. pylori therapy or maintenance therapy or suppressive therapy with a PPI). Most large studies of patients who have undergone definitive ulcer surgery were performed prior to the recognition of the role of H. pylori treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. An illustrative report included 159 patients who were followed more than 10 years after vagotomy and pyloroplasty for perforated duodenal ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/43\">",
"     43",
"    </a>",
"    ]. The perioperative mortality was 5.5 percent, ulcers recurred in 8.8 percent, and postoperative digestive sequelae, notably diarrhea and dumping, developed in 16 percent. Nevertheless, the overall results were considered to be good to excellent in almost 90 percent of survivors.",
"   </p>",
"   <p>",
"    Similar recurrence rates (but with less morbidity) have been described in patients who underwent parietal cell vagotomy, a more complex procedure that divides vagal branches to the acid-secreting portion of the stomach but preserves innervation to the antrum and thus gastric emptying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/44\">",
"     44",
"    </a>",
"    ]. Unfortunately, experience with this operation continues to decline, making its application in the emergent setting less feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Gastric ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because patients with perforated gastric ulcer tend to be older adults and have comorbidities, operation is associated with high overall mortality (ranging from 10 to 40 percent) regardless of treatment policy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59040 \" href=\"mobipreview.htm?14/35/14899\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/16,17,45-47\">",
"     16,17,45-47",
"    </a>",
"    ]. The preferred approach is partial gastrectomy because of the risk of gastric malignancy, unless the patient is at unacceptably high risk because of advanced age, comorbid disease, intraoperative instability, or severe peritoneal soilage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/47\">",
"     47",
"    </a>",
"    ]. Patch closure alone is associated with postoperative gastric obstruction in approximately 15 percent of cases and, when performed, biopsy of the ulcer is necessary to rule out malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6862535\">",
"    <span class=\"h3\">",
"     Laparoscopic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is growing experience with laparoscopic techniques for management of peptic ulcer. Graham patch, with or without a laparoscopic vagotomy, for perforated peptic ulcers is probably the most appropriate of these minimally invasive approaches in experienced hands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/45,48-50\">",
"     45,48-50",
"    </a>",
"    ]. This is far from becoming the standard of care and may not be applicable in the high risk patient or when the diagnosis is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274557\">",
"    <span class=\"h1\">",
"     ULCER PENETRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcer penetration refers to penetration of the ulcer through the bowel wall without free perforation and leakage of luminal contents into the peritoneal cavity. Surgical series suggest that penetration occurs in 20 percent of ulcers, but only a small proportion of penetrating ulcers become clinically evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Penetration occurs in descending order of frequency into the pancreas, gastrohepatic omentum, biliary tract, liver, greater omentum, mesocolon, colon, and vascular structures. Antral and duodenal ulcers can penetrate into the pancreas, while pyloric or prepyloric ulcers can penetrate the duodenum, eventually leading to a gastroduodenal fistula evident as a \"double\" pylorus. A longstanding ulcer history is common, but not invariable, in patients who develop penetration. Gastrocolic fistulae are seen with greater curvature gastric ulcers, particularly marginal ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/19,53\">",
"     19,53",
"    </a>",
"    ]. Typical features of this complication include pain, weight loss, and diarrhea; feculent vomiting is an uncommon, but diagnostic symptom. A duodenocolic fistula can also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274564\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetration often comes to attention because of a change in symptoms or involvement of adjacent structures. The change in symptom pattern may be gradual or sudden; it usually involves a loss of cyclicity of the pain with meals, and loss of relief with food and antacid. The pain typically becomes more intense, of longer duration, and is frequently referred to the lower posterior thorax or upper lumbar region.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274578\">",
"    <span class=\"h2\">",
"     Associated complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcer penetration can be associated with a wide array of uncommon complications including abscess (evident on CT or ultrasonography) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/54\">",
"     54",
"    </a>",
"    ] and erosion into vascular structures such as the aorta or cystic artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Rare biliary tract complications include erosion into the biliary tree with choledochoduodenal fistula, extrahepatic bile duct obstruction, or hematobilia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78578 \" href=\"mobipreview.htm?43/14/44262\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/57\">",
"     57",
"    </a>",
"    ]. Fistulization into the pancreatic duct has also been reported with penetrating duodenal ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/56\">",
"     56",
"    </a>",
"    ]. Mild hyperamylasemia can develop with posterior penetration of either gastric or duodenal ulcer, but clinical pancreatitis is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493274585\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of penetrating ulcers should follow the intensive measures outlined for refractory ulcers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16345?source=see_link&amp;anchor=H14#H14\">",
"     \"Refractory or recurrent peptic ulcer disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GASTRIC OUTLET OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric outlet obstruction is the least frequent ulcer complication in developed countries. Most cases are associated with duodenal or pyloric channel ulceration, with gastric ulceration accounting for only 5 percent of cases. As peptic ulcer has become less frequent, malignancy has emerged as a prominent cause of gastric outlet obstruction, despite the lower overall rates of gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44793?source=see_link&amp;anchor=H3#H3\">",
"     \"Gastric outlet obstruction in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493273602\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of gastric retention include early satiety, bloating, indigestion, anorexia, nausea, vomiting, epigastric pain, and weight loss. High-grade outlet obstruction may be present without gastric distress. Appetite and food intake may be preserved in association with delayed, large volume vomiting. Conversely, some patients may have minimal or intermittent obstruction, but complain of considerable nausea, pain, and indigestion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44793?source=see_link&amp;anchor=H15#H15\">",
"     \"Gastric outlet obstruction in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493273616\">",
"    <span class=\"h2\">",
"     Medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical management of gastric outlet obstruction includes correction of fluid and electrolyte deficits, assessment of gastric residual, antisecretory agents, and diagnostic endoscopy. In some cases, endoscopic dilation can be performed. These are outlined briefly here and presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44793?source=see_link&amp;anchor=H26#H26\">",
"     \"Gastric outlet obstruction in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Correct fluid and electrolyte deficits",
"      </strong>",
"      &ndash; Prolonged vomiting and poor fluid intake may lead to prerenal azotemia, hyponatremia, and a hypokalemic metabolic alkalosis, which should be treated with intravenous saline to restore the volume status and urine output.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"       Potassium chloride",
"      </a>",
"      should also be administered as indicated. Careful assessment of nutritional status is required; intravenous hyperalimentation should be considered in malnourished patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link\">",
"       \"Nutrition support in critically ill patients: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Measure gastric residual",
"      </strong>",
"      &ndash; After correction of fluid and electrolyte abnormalities, the initial step in the management of presumed gastric outlet obstruction is to confirm the diagnosis of gastric retention by measuring the gastric residual and performing a saline load test if the residual is less than about 250 to 300 cc (",
"      <a class=\"graphic graphic_table graphicRef63196 \" href=\"mobipreview.htm?26/29/27099\">",
"       table 2",
"      </a>",
"      ). If gastric retention is confirmed, the nasogastric tube should be replaced by a large bore Ewald tube and the stomach lavaged to remove debris. The nasogastric tube should then be reinserted, good function confirmed, and intermittent suction continued for three to five days to decompress the stomach while intravenous fluid and electrolytes are administered. Approximately one-half",
"      <strong>",
"      </strong>",
"      of cases of gastric outlet obstruction due to peptic ulcer and associated spasm, edema, inflammation, or pyloric dysmotility respond initially to this regimen.",
"     </li>",
"     <li>",
"      <strong>",
"       Use acid antisecretory agents",
"      </strong>",
"      &ndash; Even though the benefit of antisecretory therapy has not been formally established for the acute or long-term management of ulcer obstruction, these agents are the mainstay of initial treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40282?source=see_link&amp;anchor=H4460489#H4460489\">",
"       \"Overview of the complications of peptic ulcer disease\", section on 'Acid suppressive therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Identify the cause of obstruction",
"      </strong>",
"      &ndash; Once the patient has been stabilized and gastric outlet obstruction has been confirmed, the next steps are to identify and treat the underlying cause of the obstruction. Endoscopy and biopsy should be performed to exclude malignancy, diagnose ulcer disease, and determine if H. pylori is present.",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44793?source=see_link&amp;anchor=H18#H18\">",
"       \"Gastric outlet obstruction in adults\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Attempt endoscopic balloon dilation",
"      </strong>",
"      &ndash; If the pyloric channel can be identified with endoscopy and a balloon can be passed, dilation is an appropriate option in experienced hands. Before dilation, a Gastrografin study may be helpful to define the anatomy of the pylorus.",
"      <br/>",
"      <br/>",
"      If the pylorus can be opened sufficiently to allow the patient to tolerate a liquid diet, especially when the underlying cause can be reversed, continuing medical treatment is a reasonable option as long as gastric function is carefully monitored to ensure that retention does not recur. Monitoring symptoms is important, but it may be revealing to also check a gastric residual or perform a saline load test, especially in patients who remain asymptomatic despite large gastric residuals. Multiple sessions of endoscopic balloon dilation are necessary in some cases.",
"      <br/>",
"      <br/>",
"      Cases that clearly warrant surgery are ones where the pylorus is obstructed and cannot be safely dilated, or where the obstruction persists or recurs during medical management. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40282?source=see_link&amp;anchor=H4460770#H4460770\">",
"       \"Overview of the complications of peptic ulcer disease\", section on 'Endoscopic balloon dilation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493273644\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, patients with gastric outlet obstruction due to peptic ulcer traditionally were sent to surgery if they failed to respond to three days of nasogastric suction. However, in cases where the cause can be reversed (eg, H. pylori or use of NSAIDs), a more conservative approach deserves consideration. Gastric outlet obstruction is not an emergency; both endoscopic and surgical intervention should be delayed until the patient has been stabilized and fluid and electrolyte balance restored. Delays are also appropriate if the patient's nutritional status is compromised (eg, a serum albumin level",
"    <strong>",
"    </strong>",
"    less than 2.8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is a strong predictor of a poor surgical outcome) or if the stomach is markedly dilated (postoperative gastric atony appears more likely and may be prevented by preoperative decompression).",
"   </p>",
"   <p>",
"    The choice of procedure is usually made during the operation.",
"    <span class=\"nowrap\">",
"     Antrectomy/distal",
"    </span>",
"    gastrectomy, usually combined with some form of vagotomy, has been favored to relieve the obstruction and definitively rule out malignancy. Unfortunately, inflammation and scarring may prevent safe resection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    closure of the duodenal stump. In this setting, vagotomy and gastrojejunostomy, preferably with biopsy of the ulcer, has been the most common approach. Although gastrojejunostomy may theoretically reduce some of the advantages of parietal cell vagotomy (ie, preservation of gastric emptying and minimization of bile reflux), parietal cell vagotomy deserves consideration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Placement of a feeding jejunostomy tube at the time of surgery is usually recommended because of both preoperative malnutrition and the risk of delayed postoperative gastric emptying.",
"   </p>",
"   <p>",
"    Debate persists as to the optimal drainage procedure. The Jaboulay side-to-side duodenoplasty has gained popularity because of its technical simplicity and because the anastomosis is performed in healthy tissue, distinct from the ulcer bed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/62\">",
"     62",
"    </a>",
"    ]. In a randomized trial that included 90 consecutive patients with gastric outlet obstruction secondary to duodenal ulcer assigned to a parietal cell vagotomy (PCV) with gastrojejunostomy, PCV with Jaboulay duodenoplasty, or selective vagotomy with antrectomy, there were no differences in the postoperative course or the reduction in gastric acid secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/63\">",
"     63",
"    </a>",
"    ]. However, both PCV with gastrojejunostomy and selective vagotomy with antrectomy produced a clinical result superior to PCV with Jaboulay pyloroplasty.",
"   </p>",
"   <p>",
"    Concerning sequelae of surgery include gastric dysmotility and symptoms persisting beyond the early postoperative period in the absence of mechanical obstruction. Estimates of postoperative gastric dysfunction range from 10 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. The outcome will vary depending upon patient selection, the preoperative status, and surgical technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6862064\">",
"    <span class=\"h1\">",
"     DEFINITIVE ULCER SURGERY FOR ULCER COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive acid-reducing surgical procedures (eg, PCV, truncal or selective vagotomy with drainage, or partial gastrectomy) have the potential to decrease recurrent complications. However, these procedures add operative time, perioperative risk, and long-term adverse side effects, such as dumping syndrome.",
"   </p>",
"   <p>",
"    Most large studies of definitive ulcer surgery were performed prior to the recognition of H. pylori, the role of NSAIDs, and potent antisecretory agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/40,42-44\">",
"     40,42-44",
"    </a>",
"    ]. One report included 159 patients who were followed more than 10 years after vagotomy and pyloroplasty for perforated duodenal ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/43\">",
"     43",
"    </a>",
"    ]. The perioperative mortality was 5.5 percent, ulcers recurred in 8.8 percent, and postoperative digestive sequelae, notably diarrhea and dumping, developed in 16 percent. Similar recurrence rates (but with less morbidity) have been described in patients who underwent parietal cell vagotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even though no data are available to compare the risks of definitive ulcer surgery to current medical treatment, a few points are relevant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definitive surgery is not appropriate if medical management has not been attempted. Although the cause of the ulcer disease may not be known at the time of surgery, PUD (with the exception of malignant ulcers) typically responds quite well to medical management, although some patients may not tolerate, be adherent to, or respond to medical treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients who require emergency surgery for ulcer complications and have failed all forms of medical management, definitive surgery deserves consideration.",
"     </li>",
"     <li>",
"      With improved medical treatment, the rates of performing definitive ulcer procedures during emergency surgery have fallen dramatically over the past two decades [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/67-70\">",
"       67-70",
"      </a>",
"      ]. As a result, there is a decline in surgical expertise for performing these definitive procedures, especially in the community, which inevitably further compromises the outcomes of surgery.",
"     </li>",
"     <li>",
"      Curing H. pylori infection appears to decrease recurrent ulceration and perforation following simple closure of perforated duodenal, pyloric, and prepyloric ulcers, suggesting that the infection is causing the recurrences. Even after definitive ulcer surgery, H. pylori is implicated in ulcer recurrence, atrophic gastritis, and precursor lesions that may underlie the increased rate of gastric cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/71-73\">",
"       71-73",
"      </a>",
"      ]. Thus, the organism should be sought and cured in patients even after definitive ulcer surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/5/40025/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493275991\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major complications of peptic ulcer disease (PUD) include bleeding, perforation, penetration, and gastric outlet obstruction. Although a history of preceding ulcer symptoms is common, many patients have no preceding typical peptic ulcer symptoms or known disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early collaboration among emergency, gastrointestinal, intensive care unit, surgical, and radiological team members is essential for patients with complicated PUD to ensure rapid stabilization and appropriate, well coordinated care. Delays and poor coordination of care increase morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H6862161\">",
"       'Surgical consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of ulcers are due to H. pylori or use of NSAIDs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and definitive medical treatment dramatically decreases recurrences, thus it is essential to carefully search for the presence of H. pylori and for NSAID or aspirin use. (See",
"      <a class=\"local\" href=\"#H493276269\">",
"       'Underlying causes of peptic ulcer disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with bleeding ulcers, appropriate treatment includes fluid resuscitation; blood transfusions as necessary; early, high dose intravenous proton pump inhibitor (PPI), and endoscopic intervention for active bleeding. Surgery is required when a total of two endoscopic treatment sessions have failed or bleeding continues after these interventions, especially in hemodynamically unstable patients. (See",
"      <a class=\"local\" href=\"#H493274237\">",
"       'Bleeding ulcers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The early management of a perforated ulcer includes supportive measures with a nasogastric tube, volume replacement, and antibiotics. After resuscitation, emergent operation and closure with a piece of omentum (Graham patch) is the standard of care for patients with an acute perforation. (See",
"      <a class=\"local\" href=\"#H493274985\">",
"       'Perforated ulcers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ulcer penetration refers to penetration of the ulcer through the bowel wall without free perforation and leakage of luminal contents into the peritoneal cavity. (See",
"      <a class=\"local\" href=\"#H493274557\">",
"       'Ulcer penetration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastric outlet obstruction is the least frequent ulcer complication. Most cases are associated with duodenal or pyloric channel ulceration. Malignancy must be considered and excluded in patients with gastric outlet obstruction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Gastric outlet obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive acid-reducing surgical procedures (eg, parietal cell vagotomy or vagotomy with drainage or partial gastrectomy) have the potential to decrease recurrent complications. However, these procedures add operative time, perioperative risk, and long-term adverse side effects, such as dumping syndrome. Emergent definitive ulcer procedures should only be performed if the patient has previously failed a fully adequate trial of medical management. (See",
"      <a class=\"local\" href=\"#H6862064\">",
"       'Definitive ulcer surgery for ulcer complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/1\">",
"      Gustavsson S, Kelly KA, Melton LJ 3rd, Zinsmeister AR. Trends in peptic ulcer surgery. A population-based study in Rochester, Minnesota, 1956-1985. Gastroenterology 1988; 94:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/2\">",
"      Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg 2010; 251:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/3\">",
"      Towfigh S, Chandler C, Hines OJ, McFadden DW. Outcomes from peptic ulcer surgery have not benefited from advances in medical therapy. Am Surg 2002; 68:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/4\">",
"      Rockall TA. Management and outcome of patients undergoing surgery after acute upper gastrointestinal haemorrhage. Steering Group for the National Audit of Acute Upper Gastrointestinal Haemorrhage. J R Soc Med 1998; 91:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/5\">",
"      S&aacute;nchez-Delgado J, Gen&eacute; E, Su&aacute;rez D, et al. Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol 2011; 106:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/6\">",
"      Ng EK, Lam YH, Sung JJ, et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg 2000; 231:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/7\">",
"      Gisbert JP, Legido J, Garc&iacute;a-Sanz I, Pajares JM. Helicobacter pylori and perforated peptic ulcer prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Dig Liver Dis 2004; 36:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/8\">",
"      Kumar S, Mittal GS, Gupta S, et al. Prevalence of Helicobactor pylori in patients with perforated duodenal ulcer. Trop Gastroenterol 2004; 25:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/9\">",
"      Bender JS, Bouwman DL, Weaver DW. Bleeding gastroduodenal ulcers: improved outcome from a unified surgical approach. Am Surg 1994; 60:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/10\">",
"      Smith BR, Stabile BE. Emerging trends in peptic ulcer disease and damage control surgery in the H. pylori era. Am Surg 2005; 71:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/11\">",
"      Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007; 11:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/12\">",
"      M&uuml;ller T, Barkun AN, Martel M. Non-variceal upper GI bleeding in patients already hospitalized for another condition. Am J Gastroenterol 2009; 104:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/13\">",
"      Lau JY, Sung JJ, Lam YH, et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999; 340:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/14\">",
"      Hoffmann J, Devantier A, Koelle T, Jensen HE. Parietal cell vagotomy as an emergency procedure for bleeding peptic ulcer. Ann Surg 1987; 206:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/15\">",
"      Miedema BW, Torres PR, Farnell MB, et al. Proximal gastric vagotomy in the emergency treatment of bleeding duodenal ulcer. Am J Surg 1991; 161:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/16\">",
"      Herrington JL Jr, Sawyers JL. Gastric ulcer. Curr Probl Surg 1987; 24:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/17\">",
"      Jordan PH Jr. Surgery for peptic ulcer disease. Curr Probl Surg 1991; 28:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/18\">",
"      Gunshefski L, Flancbaum L, Brolin RE, Frankel A. Changing patterns in perforated peptic ulcer disease. Am Surg 1990; 56:270.",
"     </a>",
"    </li>",
"    <li>",
"     Graham DY. Ulcer complications and their nonoperative treatment. In: Gastrointestinal Disease, 5th ed, Sleisenger M, Fordtran J (Eds), WB Saunders, Philadelphia 1993. p.698.",
"    </li>",
"    <li>",
"     Silen W. Cope's Early Diagnosis of the Acute Abdomen, Oxford University Press, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/21\">",
"      Svanes C, Lie RT, Svanes K, et al. Adverse effects of delayed treatment for perforated peptic ulcer. Ann Surg 1994; 220:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/22\">",
"      M&oslash;ller MH, Adamsen S, Thomsen RW, M&oslash;ller AM. Preoperative prognostic factors for mortality in peptic ulcer perforation: a systematic review. Scand J Gastroenterol 2010; 45:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/23\">",
"      Noguiera C, Silva AS, Santos JN, et al. Perforated peptic ulcer: main factors of morbidity and mortality. World J Surg 2003; 27:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/24\">",
"      Kocer B, Surmeli S, Solak C, et al. Factors affecting mortality and morbidity in patients with peptic ulcer perforation. J Gastroenterol Hepatol 2007; 22:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/25\">",
"      Hermansson M, Sta&euml;l von Holstein C, Zilling T. Surgical approach and prognostic factors after peptic ulcer perforation. Eur J Surg 1999; 165:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/26\">",
"      Wong CH, Chow PK. Posterior perforation of gastric ulcer. Dig Dis Sci 2004; 49:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/27\">",
"      Grassi R, Romano S, Pinto A, Romano L. Gastro-duodenal perforations: conventional plain film, US and CT findings in 166 consecutive patients. Eur J Radiol 2004; 50:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/28\">",
"      Furukawa A, Sakoda M, Yamasaki M, et al. Gastrointestinal tract perforation: CT diagnosis of presence, site, and cause. Abdom Imaging 2005; 30:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/29\">",
"      Yeung KW, Chang MS, Hsiao CP, Huang JF. CT evaluation of gastrointestinal tract perforation. Clin Imaging 2004; 28:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/30\">",
"      Donovan AJ, Berne TV, Donovan JA. Perforated duodenal ulcer: an alternative therapeutic plan. Arch Surg 1998; 133:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/31\">",
"      Dumont R, Cinotti R, Lejus C, et al. The Microbiology of Community-acquired Peritonitis in Children. Pediatr Infect Dis J 2011; 30:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/32\">",
"      Johnson JR, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/33\">",
"      Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/34\">",
"      Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/35\">",
"      Crofts TJ, Park KG, Steele RJ, et al. A randomized trial of nonoperative treatment for perforated peptic ulcer. N Engl J Med 1989; 320:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/36\">",
"      Kay PH, Moore KT, Clark RG. The treatment of perforated duodenal ulcer. Br J Surg 1978; 65:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/37\">",
"      Playforth MJ, McMahon MJ. The indications for simple closure of perforated duodenal ulcers. Br J Surg 1978; 65:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/38\">",
"      Boey J, Lee NW, Koo J, et al. Immediate definitive surgery for perforated duodenal ulcers: a prospective controlled trial. Ann Surg 1982; 196:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/39\">",
"      Hay JM, Lacaine F, Kohlmann G, Fingerhut A. Immediate definitive surgery for perforated duodenal ulcer does not increase operative mortality: a prospective controlled trial. World J Surg 1988; 12:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/40\">",
"      Tanphiphat C, Tanprayoon T, Na Thalang A. Surgical treatment of perforated duodenal ulcer: a prospective trial between simple closure and definitive surgery. Br J Surg 1985; 72:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/41\">",
"      Datsis AC, Rogdakis A, Kekelos S, et al. Simple closure of chronic duodenal ulcer perforation in the era of Helicobacter pylori: an old procedure, today's solution. Hepatogastroenterology 2003; 50:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/42\">",
"      Wara P, Kristensen ES, S&oslash;rensen FH, et al. The value of parietal cell vagotomy compared to simple closure in a selective approach to perforated duodenal ulcer. Operative morbidity and recurrence rate. Acta Chir Scand 1983; 149:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/43\">",
"      Robles R, Parrilla P, Lujan JA, et al. Long-term follow-up of bilateral truncal vagotomy and pyloroplasty for perforated duodenal ulcer. Br J Surg 1995; 82:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/44\">",
"      Jordan PH Jr, Thornby J. Perforated pyloroduodenal ulcers. Long-term results with omental patch closure and parietal cell vagotomy. Ann Surg 1995; 221:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/45\">",
"      Lau WY, Leung KL, Zhu XL, et al. Laparoscopic repair of perforated peptic ulcer. Br J Surg 1995; 82:814.",
"     </a>",
"    </li>",
"    <li>",
"     Matthews JB, Silen W. Operations for peptic ulcer disease and early postoperative complications. In: Gastrointestinal Disease, Sleisenger MH, Fordtran JS (Eds), WB Saunders, Philadelphia 1993. p.713.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/47\">",
"      Hodnett RM, Gonzalez F, Lee WC, et al. The need for definitive therapy in the management of perforated gastric ulcers. Review of 202 cases. Ann Surg 1989; 209:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/48\">",
"      Lau WY, Leung KL, Kwong KH, et al. A randomized study comparing laparoscopic versus open repair of perforated peptic ulcer using suture or sutureless technique. Ann Surg 1996; 224:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/49\">",
"      Zittel TT, Jehle EC, Becker HD. Surgical management of peptic ulcer disease today--indication, technique and outcome. Langenbecks Arch Surg 2000; 385:84.",
"     </a>",
"    </li>",
"    <li>",
"     Nakamura T, Yoshida M, Otani Y, et al. Twelve years' progress in surgery for perforated gastric and duodenal ulcers: a retrospective study of indications for laparoscopic surgery, post-operative course and the influence of Candida infection. Alimentary Pharmacology &amp; Therapeutics Symposium Series 2006; 2:297.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/51\">",
"      Lunevicius R, Morkevicius M. Systematic review comparing laparoscopic and open repair for perforated peptic ulcer. Br J Surg 2005; 92:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/52\">",
"      NORRIS JR, HAUBRICH WS. The incidence and clinical features of pentration in peptic ulceration. JAMA 1961; 178:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/53\">",
"      Soybel DI, Kestenberg A, Brunt EM, Becker JM. Gastrocolic fistula as a complication of benign gastric ulcer: report of four cases and update of the literature. Br J Surg 1989; 76:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/54\">",
"      Ranschaert E, Rigauts H. Confined gastric perforation: ultrasound and computed tomographic diagnosis. Abdom Imaging 1993; 18:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/55\">",
"      Ford GA, Simpson AH, Gear MW, Wilkinson SP. Duodenal ulceration into the cystic artery. Postgrad Med J 1990; 66:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/56\">",
"      Merrill JR. Fistulation to the pancreatic duct complicating duodenal peptic ulcer. Gastroenterology 1984; 87:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/57\">",
"      Van Steenbergen W, Ponette E, Marchal G, et al. Distal common bile duct stenosis secondary to benign duodenal ulceration: report of a case. Gastrointest Radiol 1990; 15:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/58\">",
"      Shone DN, Nikoomanesh P, Smith-Meek MM, Bender JS. Malignancy is the most common cause of gastric outlet obstruction in the era of H2 blockers. Am J Gastroenterol 1995; 90:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/59\">",
"      Johnson CD, Ellis H. Gastric outlet obstruction now predicts malignancy. Br J Surg 1990; 77:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/60\">",
"      Donahue PE, Yoshida J, Richter HM, et al. Proximal gastric vagotomy with drainage for obstructing duodenal ulcer. Surgery 1988; 104:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/61\">",
"      Donahue PE, Griffith C, Richter HM. A 50-year perspective upon selective gastric vagotomy. Am J Surg 1996; 172:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/62\">",
"      Dittrich K, Blauensteiner W, Schrutka-K&ouml;lbl C, et al. Highly selective vagotomy plus Jaboulay: a possible alternative in patients with benign stenosis secondary to duodenal ulceration. J Am Coll Surg 1995; 180:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/63\">",
"      Csendes A, Maluenda F, Braghetto I, et al. Prospective randomized study comparing three surgical techniques for the treatment of gastric outlet obstruction secondary to duodenal ulcer. Am J Surg 1993; 166:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/64\">",
"      McCallum RW, Polepalle SC, Schirmer B. Completion gastrectomy for refractory gastroparesis following surgery for peptic ulcer disease. Long-term follow-up with subjective and objective parameters. Dig Dis Sci 1991; 36:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/65\">",
"      Hom S, Sarr MG, Kelly KA, Hench V. Postoperative gastric atony after vagotomy for obstructing peptic ulcer. Am J Surg 1989; 157:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/66\">",
"      Stabile BE. Redefining the role of surgery for perforated duodenal ulcer in the Helicobacter pylori era. Ann Surg 2000; 231:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/67\">",
"      Sarosi GA Jr, Jaiswal KR, Nwariaku FE, et al. Surgical therapy of peptic ulcers in the 21st century: more common than you think. Am J Surg 2005; 190:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/68\">",
"      Chiu PW, Ng EK, Wong SK, et al. Surgical salvage of bleeding peptic ulcers after failed therapeutic endoscopy. Dig Surg 2009; 26:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/69\">",
"      Smith BR, Wilson SE. Impact of nonresective operations for complicated peptic ulcer disease in a high-risk population. Am Surg 2010; 76:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/70\">",
"      Abe N, Takeuchi H, Yanagida O, et al. Surgical indications and procedures for bleeding peptic ulcer. Dig Endosc 2010; 22 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/71\">",
"      Turnage RH, Sarosi G, Cryer B, et al. Evaluation and management of patients with recurrent peptic ulcer disease after acid-reducing operations: a systematic review. J Gastrointest Surg 2003; 7:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/72\">",
"      Giuliani A, Galati G, Demoro M, et al. Screening of Helicobacter pylori infection after gastrectomy for cancer or peptic ulcer: results of a cohort study. Arch Surg 2010; 145:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/5/40025/abstract/73\">",
"      Lindsetmo RO, Eide TJ, Johnsen R, Revhaug A. Helicobacter pylori-induced damage to the gastric mucosa is not modulated by previous vagotomy or medical treatment of peptic ulcer disease: a comparative study of vagotomized patients, medically treated peptic ulcer patients and community control subjects. World J Surg 2008; 32:2267.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8040 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40025=[""].join("\n");
var outline_f39_5_40025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H493275991\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6861940\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H493276269\">",
"      UNDERLYING CAUSES OF PEPTIC ULCER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6862161\">",
"      SURGICAL CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H493274237\">",
"      BLEEDING ULCERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493274244\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493274251\">",
"      Indications for surgery for a bleeding ulcer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H493274258\">",
"      - Bleeding duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H493274265\">",
"      - Bleeding gastric ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H493274985\">",
"      PERFORATED ULCERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493274992\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493274999\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493275006\">",
"      Early management of perforated ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H493275028\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493275520\">",
"      Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Gastric ulcer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6862535\">",
"      - Laparoscopic approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H493274557\">",
"      ULCER PENETRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493274564\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493274578\">",
"      Associated complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493274585\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GASTRIC OUTLET OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493273602\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493273616\">",
"      Medical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493273644\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6862064\">",
"      DEFINITIVE ULCER SURGERY FOR ULCER COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H493275991\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8040\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8040|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/12/18639\" title=\"diagnostic image 1\">",
"      Perforated duodenal ulcer on fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/59/17331\" title=\"diagnostic image 2\">",
"      Perforated duodenal ulcer on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/30/21999\" title=\"diagnostic image 3\">",
"      Duodenal ulcer on fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/34/9762\" title=\"diagnostic image 4\">",
"      Penetrating duodenal ulcer on fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/35/14899\" title=\"diagnostic image 5\">",
"      Gastric ulcer on fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/14/44262\" title=\"diagnostic image 6\">",
"      Duodenal ulcer with penetration into biliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8040|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/7/15475\" title=\"figure 1\">",
"      Billroth reconstruction following gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8040|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/45/9949\" title=\"table 1\">",
"      Operative versus nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/29/27099\" title=\"table 2\">",
"      Saline load test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=related_link\">",
"      Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=related_link\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44793?source=related_link\">",
"      Gastric outlet obstruction in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40282?source=related_link\">",
"      Overview of the complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37960?source=related_link\">",
"      Pathogenic Escherichia coli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16345?source=related_link\">",
"      Refractory or recurrent peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33688?source=related_link\">",
"      Role of surgery in the management of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_5_40026="Necrolytic migratory erythema perioral";
var content_f39_5_40026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76162%7EDERM%2F56367%7EONC%2F73263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76162%7EDERM%2F56367%7EONC%2F73263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Necrolytic migratory erythema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous plaques, erosions, and crusts are present periorally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Necrolytic migratory erythema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 519px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous patches and erosions with peripheral crusts are present in this patient with necrolytic migratory erythema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Necrolytic migratory erythema (Glucagonoma syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory dermatosis with angular cheilitis, and inflammatory, scaly, and erosive plaques around the nose, mouth, and medial aspects of the eyes (left panel). The right panel depicts polycyclic erosions in the anogenital region with necrotic flaccid epidermis still covering part of these erosions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Color Atlas and Synopsis of Clinical Dermatology, 3rd edition, Fitzpatrick, et al (Eds), McGraw-Hill, New York 1997. Copyright &copy; 1997 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40026=[""].join("\n");
var outline_f39_5_40026=null;
var title_f39_5_40027="ACOG CPP Rx A recs";
var content_f39_5_40027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of recommendations for treatment of chronic pelvic pain from the American College of Obstetricians and Gynecologists",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Recommendations based on good, consistent scientific evidence (level A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle2\">",
"        Indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combined oral contraceptive pills",
"       </td>",
"       <td>",
"        Primary dysmenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GnRH agonists",
"       </td>",
"       <td>",
"        Endometriosis, irritable bowel syndrome (may be given empirically in women with symptoms consistent with endometriosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsteroidal anit-inflammatory drugs",
"       </td>",
"       <td>",
"        Dysmenorrhea, moderate pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progestins (daily, high dose)",
"       </td>",
"       <td>",
"        Endometriosis, pelvic congestion syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laparoscopic ablation/resection of endometriosis",
"       </td>",
"       <td>",
"        Stage I-III endometriosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presacral neurectomy",
"       </td>",
"       <td>",
"        Centrally located dysmenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine nerve ablation",
"       </td>",
"       <td>",
"        Not indicated",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adjunctive psychotherapy",
"       </td>",
"       <td>",
"        CPP",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Daniels J, Gray R, Hills RK, et al. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial. JAMA 2009; 302:955.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40027=[""].join("\n");
var outline_f39_5_40027=null;
var title_f39_5_40028="Localized cutaneous blistering disorders";
var content_f39_5_40028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Select examples of localized cutaneous blistering disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dermatitis",
"        </strong>",
"       </td>",
"       <td>",
"        Linear configuration if contact dermatitis.",
"       </td>",
"       <td>",
"        H&amp;E: spongiosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Bullous tinea pedis",
"        </strong>",
"       </td>",
"       <td>",
"        Vesicles on soles of feet or between the toes.",
"       </td>",
"       <td>",
"        KOH examination demonstrating hyphae or positive fungal culture",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Fixed drug eruption",
"        </strong>",
"       </td>",
"       <td>",
"        Dusky violaceous patch, hemorrhagic bulla; may recur at same location with future drug exposures.",
"       </td>",
"       <td>",
"        <p>",
"         History",
"        </p>",
"        <p>",
"         H&amp;E: lichenoid or interface dermatitis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Erythema multiforme",
"        </strong>",
"       </td>",
"       <td>",
"        Targetoid papules on extremities and acral locations; hemorrhagic vesicles/bullae; intermittent recurrences usually associated with HSV infection.",
"       </td>",
"       <td>",
"        H&amp;E: vacuolar interface dermatitis; positive confirmation of concurrent HSV outbreak",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Friction blisters",
"        </strong>",
"       </td>",
"       <td>",
"        Most commonly seen on soles of feet or palms of hands at sites of friction.",
"       </td>",
"       <td>",
"        <p>",
"         History",
"        </p>",
"        <p>",
"         H&amp;E: intraepidermal blister",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Coma blisters",
"        </strong>",
"       </td>",
"       <td>",
"        Tense blisters at sites of pressure in comatose patients.",
"       </td>",
"       <td>",
"        <p>",
"         History",
"        </p>",
"        <p>",
"         H&amp;E: subepidermal blister and eccrine gland necrosis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Bullous insect bites",
"        </strong>",
"       </td>",
"       <td>",
"        Intense pruritus and erythematous papules.",
"       </td>",
"       <td>",
"        History",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Bullous disease of diabetes (bullous diabeticorum)",
"        </strong>",
"       </td>",
"       <td>",
"        Tense blisters found predominately on lower extremities. Lack of erythema or inflammation. Rare manifestation of diabetes.",
"       </td>",
"       <td>",
"        <p>",
"         H&amp;E: pauci-inflammatory subepidermal blister",
"        </p>",
"        <p>",
"         DIF: negative",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Grover's (transient acantholytic dermatosis)",
"        </strong>",
"       </td>",
"       <td>",
"        Keratotic eroded papules and vesicles on the abdomen, chest, back. Male predominance. Often worsens with heat, exercise, hospitalization.",
"       </td>",
"       <td>",
"        <p>",
"         H&amp;E: dyskeratosis and acantholysis",
"        </p>",
"        <p>",
"         DIF: negative",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H&amp;E: hematoxylin and eosin pathology stain; DIF: direct immunofluorescence; KOH: potassium hydroxide; HSV: herpes simplex virus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40028=[""].join("\n");
var outline_f39_5_40028=null;
var title_f39_5_40029="MV repair symptom heart failure";
var content_f39_5_40029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral valve repair for mitral regurgitation in heart failure improves symptoms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with mitral regurgitation due to a congestive cardiomyopathy, mitral annuloplasty resulted in a significant improvement in symptoms and functional status at 17 weeks; NYHA functional class fell significantly from an average of 3.9 to 1.7 (p &lt;0.001*).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bach DS, Bolling SF. Am Heart J 1995; 129:1165.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40029=[""].join("\n");
var outline_f39_5_40029=null;
var title_f39_5_40030="Ampullary carcinoma algorithm";
var content_f39_5_40030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ampullary carcinoma algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 467px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40030=[""].join("\n");
var outline_f39_5_40030=null;
var title_f39_5_40031="PTC after hepaticojejunostomy";
var content_f39_5_40031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepaticojejunostomy for complete transection of the common bile duct after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram of a patient with a complete transection of the common bile duct treated with hepaticojejunostomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_5_40031=[""].join("\n");
var outline_f39_5_40031=null;
